[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5336
1. Custódio G, Locks LH, Coan MF, Gonçalves CO, Trevisol DJ, Trevisol FS: Epidemiology of basal cell carcinomas in Tubarão, Santa Catarina (SC), Brazil between 1999 and 2008. An Bras Dermatol; 2010 Nov-Dec;85(6):819-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of basal cell carcinomas in Tubarão, Santa Catarina (SC), Brazil between 1999 and 2008.
  • BACKGROUND: Skin cancer is the most frequent type of neoplasm in Brazil.
  • There are no data on the incidence of basal cell carcinoma in the Southern region of Santa Catarina.
  • OBJECTIVE: To establish epidemiological data on basal cell carcinoma in Tubarão, Santa Catarina, between 1999 and 2008.
  • METHODS: A cross-sectional study was conducted in which anatomopathological reports of basal cell carcinoma from the laboratories of Tubarão, Santa Catarina, were analyzed.
  • We considered the following variables: year of diagnosis, age, gender, city of origin, tumor site, histological subtype, lesion diameter, margin involvement, and relapse.
  • RESULTS: Reports of 3,253 subjects most frequently between the ages of 61 and 80 years diagnosed with basal cell carcinoma were obtained.
  • The incidence of basal cell carcinoma was 164.5 cases per 100,000 inhabitants in 1999 and 295.2 per 100,000 in 2008, showing an increase of 80%.
  • There was an association between males and basal cell carcinoma of the torso and ear, and between females and basal cell carcinoma of the nose.
  • Based on multivariate analysis, lesions of 2 cm in diameter were 5.5 times more likely to present margin involvement, and basal cell carcinoma of the face was 1.8 times more likely to occur (p <0.0001).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308305.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Lo BK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ: CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol; 2010 May;176(5):2435-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas.
  • Basal cell carcinoma (BCC) is the most common skin malignancy encountered worldwide.
  • We hypothesized that CXC chemokines, small cytokines involved in inducing directed leukocyte chemotaxis, could play a key role in the modulation of BCC growth.
  • In this study, quantitative RT-PCR revealed that the chemokines CXCL9, 10, 11, and their receptor CXCR3 were significantly upregulated by an average 22.6-fold, 9.2-fold, 26.6-fold, and 4.9-fold, respectively in BCC tissue samples as compared with nonlesional skin epithelium.
  • Immunohistochemistry analysis revealed that CXCR3, CXCL10, and CXCL11, but not CXCL9, colocalized with cytokeratin 17 (K17) in BCC keratinocytes.
  • In addition, CXCR3 and its ligands were expressed in cells of the surrounding BCC stroma.
  • Exposure of HaCaT cells or primary BCC-derived cells to CXCL11 peptides in vitro significantly increased cell proliferation.
  • In primary BCC-derived cell cultures, addition of CXCL11 progressively selected for K17+/CXCR3+ co-expressing cells over time.
  • The expression of CXCR3 and its ligands in human BCC keratinocytes, the enhancement of keratinocyte cell proliferation by CXCL11, and the homogeneity of K17+ BCC cells in human BCC-isolated cell population supported by CXCR3/CXCL11 signaling all suggest that CXCR3 and its ligands may be important autocrine and/or paracrine signaling mediators in the tumorigenesis of BCC.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1999 May 31;145(5):927-32 [10352011.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):71-6 [10508856.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):596-9 [16522748.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):32-42 [17591951.001]
  • [Cites] Hum Pathol. 2007 Nov;38(11):1676-87 [17707463.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):50-6 [17721996.001]
  • [Cites] J Am Acad Dermatol. 2008 Jan;58(1):158-67 [18158927.001]
  • [Cites] N Engl J Med. 2008 Jan 24;358(4):393-401 [18216361.001]
  • [Cites] J Immunol Methods. 2008 Feb 29;331(1-2):140-6 [18234207.001]
  • [Cites] Am J Dermatopathol. 2008 Jun;30(3):249-55 [18496426.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1187-96 [18375741.001]
  • [Cites] J Invest Dermatol. 2008 Jul;128(7):1797-805 [18200053.001]
  • [Cites] J Neuroimmunol. 2008 Aug 13;199(1-2):35-45 [18538864.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):835-43 [18688030.001]
  • [Cites] Arch Dermatol Res. 2010 Mar;302(2):113-23 [19517126.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):780-9 [10597195.001]
  • [Cites] J Immunol. 2000 Jan 15;164(2):733-8 [10623817.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1224-9 [11122025.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9945-54 [11136732.001]
  • [Cites] J Intern Med. 2001 Aug;250(2):91-104 [11489059.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1567-79 [11583982.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45098-105 [11571298.001]
  • [Cites] Am J Dermatopathol. 2001 Dec;23(6):501-9 [11801790.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):933-41 [12370271.001]
  • [Cites] Int J Dermatol. 2002 Oct;41(10):652-8 [12390187.001]
  • [Cites] J Histochem Cytochem. 2002 Nov;50(11):1425-34 [12417607.001]
  • [Cites] Leukemia. 2003 Jan;17(1):203-10 [12529679.001]
  • [Cites] J Invest Dermatol. 2003 Jul;121(1):191-7 [12839581.001]
  • [Cites] BMJ. 2003 Oct 4;327(7418):794-8 [14525881.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2451-8 [14633617.001]
  • [Cites] Cancer Lett. 2004 Apr 30;207(2):221-7 [15072832.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4010-7 [15173015.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):389-402 [15197337.001]
  • [Cites] J Cell Biol. 1982 Oct;95(1):285-95 [6183270.001]
  • [Cites] J Invest Dermatol. 1983 Jul;81(1 Suppl):33s-40s [6345690.001]
  • [Cites] Lancet. 1987 Aug 22;2(8556):443-6 [2887739.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] Br J Dermatol. 1990 Mar;122(3):399-403 [2322501.001]
  • [Cites] Int J Cancer. 1990 Sep 15;46(3):356-61 [2394501.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] Dermatol Clin. 1991 Oct;9(4):751-5 [1934649.001]
  • [Cites] J Invest Dermatol. 1992 Jan;98(1):45-9 [1370231.001]
  • [Cites] Int J Cancer. 1993 Feb 20;53(4):585-90 [8436431.001]
  • [Cites] Carcinogenesis. 1993 May;14(5):833-9 [8504475.001]
  • [Cites] Acta Derm Venereol. 1993 Aug;73(4):286-92 [7506469.001]
  • [Cites] Oncogene. 1995 Sep 7;11(5):961-9 [7675455.001]
  • [Cites] Br J Dermatol. 1995 Oct;133(4):501-11 [7577575.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Am J Dermatopathol. 1997 Aug;19(4):341-50 [9261468.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):436-45 [9459648.001]
  • [Cites] J Photochem Photobiol B. 1998 Mar;42(3):167-79 [9595706.001]
  • [Cites] J Invest Dermatol. 1998 Jun;110(6):885-8 [9620294.001]
  • [Cites] Blood. 2000 Jan 15;95(2):627-32 [10627472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3438-43 [10725363.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):6234-40 [15528361.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Dtsch Dermatol Ges. 2005 Jul;3(7):493-503 [15967008.001]
  • [Cites] Amyloid. 2005 Mar;12(1):41-7 [16076610.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1657-67 [15905207.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L909-18 [16339779.001]
  • [Cites] Br J Dermatol. 2006 May;154(5):910-8 [16634895.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2427-33 [16638848.001]
  • [Cites] Am J Dermatopathol. 2006 Aug;28(4):293-307 [16871032.001]
  • [Cites] Exp Dermatol. 2006 Sep;15(9):667-77 [16881963.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9509-18 [17018607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14842-7 [17003113.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1489-97 [17082008.001]
  • [Cites] Eur J Immunol. 2007 Feb;37(2):338-50 [17274000.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3396-405 [17409450.001]
  • [Cites] Endocrinology. 2007 May;148(5):2317-25 [17255201.001]
  • [Cites] Int J Exp Pathol. 2000 Jun;81(3):183-9 [10971739.001]
  • [Cites] J Dermatol Sci. 1998 May;17(1):15-23 [9651824.001]
  • [Cites] Int J Cancer. 1998 Nov 23;78(5):587-93 [9808527.001]
  • [Cites] Eur J Immunol. 1998 Nov;28(11):3696-705 [9842912.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 2):2682-6 [10068274.001]
  • [CommentIn] Am J Pathol. 2010 May;176(5):2088-91 [20185576.001]
  • (PMID = 20228225.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MUS-94025
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL11 protein, human; 0 / Chemokine CXCL11; 0 / Ligands; 0 / Receptors, CXCR3
  • [Other-IDs] NLM/ PMC2861108
  •  go-up   go-down


3. Karen JK, Gareau DS, Dusza SW, Tudisco M, Rajadhyaksha M, Nehal KS: Detection of basal cell carcinomas in Mohs excisions with fluorescence confocal mosaicing microscopy. Br J Dermatol; 2009 Jun;160(6):1242-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of basal cell carcinomas in Mohs excisions with fluorescence confocal mosaicing microscopy.
  • BACKGROUND: High-resolution real-time imaging of human skin is possible with a confocal microscope either in vivo or in freshly excised tissue ex vivo.
  • OBJECTIVES: To evaluate the sensitivity and specificity of ex vivo real-time imaging with fluorescence confocal mosaicing microscopy, using acridine orange, for the detection of residual basal cell carcinoma (BCC) in Mohs fresh tissue excisions.
  • METHODS: Forty-eight discarded skin excisions were collected following completion of Mohs surgery, consisting of excisions with and without residual BCC of all major subtypes.
  • Two Mohs surgeons, who were blinded to the cases, independently assessed confocal submosaics and recorded the presence or absence of BCC, location, and histological subtype(s).
  • RESULTS: The overall sensitivity and specificity of detecting residual BCC was 96.6% and 89.2%, respectively.
  • Very good correlation was observed between confocal mosaics and matched Mohs frozen sections for benign and malignant skin structures, overall tumour burden and location, and identification of all major histological subtypes of BCC.
  • CONCLUSIONS: Fluorescent confocal mosaicing microscopy using acridine orange enables detection of residual BCC of all subtypes in Mohs fresh tissue excisions with high accuracy.
  • This observation is an important step towards the long-term clinical goal of using a noninvasive imaging modality for potential real-time surgical pathology-at-the-bedside for skin and other tissues.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mohs Surgery / methods. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Microscopy, Confocal / methods. Microscopy, Fluorescence / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1 [11114647.001]
  • [Cites] J Microsc. 2009 Jan;233(1):149-59 [19196421.001]
  • [Cites] Arch Dermatol. 2004 Jun;140(6):736-42 [15210467.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):923-8 [15313861.001]
  • [Cites] J Cell Biol. 1985 Apr;100(4):1309-23 [3920227.001]
  • [Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1470-8 [15606734.001]
  • [Cites] J Biomed Opt. 2005 May-Jun;10(3):034009 [16229653.001]
  • [Cites] Br J Dermatol. 2006 Feb;154(2):305-9 [16433801.001]
  • [Cites] Opt Lett. 2006 Apr 1;31(7):942-4 [16599219.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):408-12 [16908344.001]
  • [Cites] Opt Lett. 2006 Sep 15;31(18):2756-8 [16936882.001]
  • [Cites] J Biomed Opt. 2007 Jan-Feb;12(1):014005 [17343480.001]
  • [Cites] Appl Opt. 2007 Apr 1;46(10):1843-51 [17356629.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034004 [17614712.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • [Cites] Lasers Surg Med. 2007 Oct;39(9):696-705 [17960751.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051901 [17994884.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1248-55 [17989735.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):152-61 [18460029.001]
  • [Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044016 [19021344.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • (PMID = 19416248.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NIBIB NIH HHS / EB / R01 EB002715; United States / NIBIB NIH HHS / EB / R01 EB002715-05; United States / NIBIB NIH HHS / EB / R01EB002715
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS95359; NLM/ PMC2693082
  •  go-up   go-down


Advertisement
4. Walter A, Barysch MJ, Behnke S, Dziunycz P, Schmid B, Ritter E, Gnjatic S, Kristiansen G, Moch H, Knuth A, Dummer R, van den Broek M: Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res; 2010 Jul 15;16(14):3562-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas.
  • PURPOSE: Nonmelanoma skin cancer is the most common cancer and comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • To find an explanation for the selective immunosurveillance of SCC, we investigated the expression of cancer-testis (CT) antigens and MHC class I (MHC-I) and the infiltration by immune cells in BCC and SCC.
  • EXPERIMENTAL DESIGN: We determined the expression of 23 different CT-antigens in 63 BCC and 40 SCC biopsies of immunocompetent and in 20 biopsies of immunosuppressed SCC patients by reverse transcription-PCR and immunohistochemistry.
  • MHC-I expression and CD8(+) T-cell infiltration were analyzed by immunohistochemistry in BCC and SCC of immunocompetent and immunosuppressed patients and in imiquimod-treated BCC patients.
  • RESULTS: We found expression of at least one CT-antigen in 81% of BCC and in 40% of SCC.
  • Most SCC, but not BCC, expressed MHC-I and were infiltrated with CD8(+) cells.
  • Imiquimod-treated BCC expressed MHC-I and were infiltrated by CD8(+) T cells.
  • CONCLUSIONS: We propose that immunosurveillance controls SCC, but not BCC, because the latter lacks MHC-I.
  • This fits with the increased incidence of SCC in immunosuppressed individuals and may explain the relatively low prevalence of CT-antigen expression in SCC as a result of CD8(+) T-cell-driven immunoediting.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Carcinoma, Basal Cell / immunology. Carcinoma, Squamous Cell / immunology. Histocompatibility Antigens Class I / biosynthesis. Monitoring, Immunologic. Skin Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20519358.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


5. Pilloni L, Bianco P, Manieli C, Senes G, Coni P, Atzori L, Aste N, Faa G: Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas. Eur J Histochem; 2009 Apr-Jun;53(2):113-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas.
  • Basal cell carcinoma (BCC) is a very common malignant skin tumor that rarely metastatizes, but is often locally aggressive.
  • These morphological features seem to be more determinant in mideface localized BCC, which frequently show a significantly higher recurrence rate.
  • An immunohistochemical profile, characterized by reactivity of tumor cells for p53, Ki67 and alpha-SMA has been associated with a more aggressive behaviour in large BCCs.
  • The aim of this study was to verify if also little (<3 cm) basal cell carcinomas can express immunohistochemical markers typical for an aggressive behaviour.
  • [MeSH-major] Actins / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19683985.001).
  • [ISSN] 1121-760X
  • [Journal-full-title] European journal of histochemistry : EJH
  • [ISO-abbreviation] Eur J Histochem
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


6. Aigner BA, Darsow U, Grosber M, Ring J, Plötz SG: Multiple basal cell carcinomas after long-term exposure to hydrazine: case report and review of the literature. Dermatology; 2010;221(4):300-2
Hazardous Substances Data Bank. HYDRAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple basal cell carcinomas after long-term exposure to hydrazine: case report and review of the literature.
  • It is known to be a skin sensitizer, a corrosive agent and it causes dermatitis on contact.
  • The authors report the case of a 68-year-old man with multiple basal cell carcinomas (BCCs) covering his arms and face.
  • The present case report strongly suggests that there may be a correlation between the long-term exposure to hydrazine and an increased risk for multiple BCCs.
  • [MeSH-major] Hydrazines / toxicity. Occupational Diseases / chemically induced. Occupational Exposure. Skin Neoplasms / chemically induced
  • [MeSH-minor] Aged. Arm. Carcinoma, Basal Cell / chemically induced. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Face. Hamartoma Syndrome, Multiple. Humans. Male

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. HYDRAZINE SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21099194.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Hydrazines; 27RFH0GB4R / hydrazine; Basal cell carcinoma, multiple
  •  go-up   go-down


7. Walker P, Hill D: Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol; 2006 Feb;47(1):1-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of basal cell carcinomas using standard postoperative histological assessment.
  • SUMMARY Surgical treatment of basal cell carcinomas using postoperative histological assessment is routinely practised in Australia.
  • The first is case selection that requires an understanding of the limitations of the procedure.
  • The merits of careful clinical follow up of incompletely excised tumours or immediate re-excision are discussed.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Education, Medical, Continuing. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Reoperation. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405477.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 95
  •  go-up   go-down


8. Elamin I, Zecević RD, Vojvodić D, Medenica L, Pavlović MD: Cytokine concentrations in basal cell carcinomas of different histological types and localization. Acta Dermatovenerol Alp Pannonica Adriat; 2008 Jun;17(2):55-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine concentrations in basal cell carcinomas of different histological types and localization.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common malignant skin tumor.
  • Cytokines as major mediators of the immune system have been shown to play an important role in biology of the neoplasm with the general predomination of Th2 cytokines, whereas IFN-?
  • OBJECTIVE: We were interested in comparing cytokine levels in BCC and cutaneous squamous cell tumors with BCC of different localization and histological subtypes.
  • MATERIAL AND METHODS: Explants from freshly excised BCC from 18 patients, and cutaneous squamous cell tumors (solar keratoses and Bowen's disease) from 9 patients were cultivated for 24 h.
  • Cytokine (IL- 2, IFN-gamma, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, TNFalpha, IL-1beta) concentrations in culture supernatants were determined by a sandwich immunoassay.
  • RESULTS: Tissue explants of BCC contained significantly higher concentrations of IL-1beta, IL-4, IL-5, and IL-6 compared to those of squamous cell tumors.
  • Interleukin-6 concentrations were higher in aggressive BCC variants (infiltrative and micronodular), but the difference was not statistically significant (p = 0.068).
  • CONCLUSIONS: Confirming the earlier findings that BCC is a tumor with a Th2 cytokine microenvironment, this study further shows that BCC situated on the head and neck produce even more of certain Th2 cytokines (IL-4 and IL-5) and TNF-alpha, a crucial immunosuppressive cytokine released upon UVB irradiation.
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. Cytokines / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / chemistry. Female. Humans. Interleukin-4 / analysis. Interleukin-5 / analysis. Male. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709290.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-5; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4
  •  go-up   go-down


9. Bernard P, Dupuy A, Sasco A, Brun P, Duru G, Nicoloyannis N, Grob JJ: Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey. Dermatology; 2008;216(3):194-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey.
  • BACKGROUND: Most actinic keratoses (AKs) and a number of basal cell carcinomas (BCCs) cannot be assessed by pathological records.
  • OBJECTIVE: To estimate prospectively the figures and characteristics of BCCs and AKs seen by French dermatologists, their medical load, and present a more realistic approach to their incidence.
  • Out-patients seen for 1 or more BCCs or AKs were recorded over 4 non-consecutive weeks.
  • RESULTS: Among 78,300 out-patients, 1,321 had 1 (or more) BCC, and 3,688 had 1 or more AKs (1 and 5% of consultations made by dermatologists).
  • When extrapolating, the medical load in France was estimated at 248,000 and 693,000 consultations/year leading to a clinical diagnosis of BCC and AK, respectively.
  • A total of 1,655 BCCs were diagnosed including 839 superficial (50.7%), 636 nodular (38.4%), 137 morpheiform (8.3%) and 43 other types (2.6%).
  • Superficial and nodular BCCs were more frequently diagnosed with a small size (<10 mm) than morpheiform BCCs.
  • CONCLUSION: Our study in France provides the first estimate of the clinical burden represented by AKs and BCCs in dermatology practice.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Keratosis / epidemiology. Skin Neoplasms / epidemiology. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182809.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


10. Wisgerhof HC, Edelbroek JR, de Fijter JW, Haasnoot GW, Claas FH, Willemze R, Bavinck JN: Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation; 2010 May 27;89(10):1231-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors.
  • BACKGROUND: The risk of skin cancer is highly increased in kidney-transplant recipients (KTR), but the risk of subsequent skin cancers is less well studied.
  • The aim of this study was to estimate the cumulative incidence of subsequent squamous- and basal-cell carcinomas (BCCs) and to analyze potential risk factors.
  • METHODS: All histologically confirmed skin cancers between 1966 and 2006 were included in the study and counted.
  • Cumulative incidences of subsequent squamous- and BCCs were calculated using Kaplan-Meier survival analyses.
  • RESULTS: A total of 239 (13%) of 1906 KTR developed skin cancer of whom 222 were diagnosed in our hospital.
  • Altogether 167 (75%) of these 222 patients developed multiple skin cancers.
  • The cumulative incidence of a second skin cancer increased from 32%, 1 year, to 59%, 3 years, and 72%, 5 years after the first skin cancer.
  • KTR who started with squamous-cell carcinoma (SCC) mainly developed SCC and recipients who started with BCC mainly developed BCC as second skin cancer.
  • Immunosuppression with azathioprine in combination with prednisone was associated with a significantly increased risk of subsequent SCCs but not with subsequent BCCs.
  • CONCLUSION: Skin cancer multiplicity is common in KTR.
  • Patients with a first skin cancer are at increased risk for more skin cancers and need to be carefully checked for subsequent skin cancers.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Kidney Transplantation / adverse effects. Skin Neoplasms / epidemiology
  • [MeSH-minor] Azathioprine / adverse effects. Azathioprine / therapeutic use. Female. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Prednisone / adverse effects. Prednisone / therapeutic use. Proportional Hazards Models. Retrospective Studies. Risk Factors. Sunlight / adverse effects. Time Factors

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20410852.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone
  •  go-up   go-down


11. Simeonov R, Simeonova G: Comparative morphometric analysis of recurrent and nonrecurrent canine basal cell carcinomas: a preliminary report. Vet Clin Pathol; 2010 Mar;39(1):96-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative morphometric analysis of recurrent and nonrecurrent canine basal cell carcinomas: a preliminary report.
  • BACKGROUND: Most reports of canine basal cell carcinomas (BCCs) focus on morphologic appearance rather than biologic behavior.
  • OBJECTIVE: The aim of the present study was to compare quantitative nuclear parameters of canine BCCs that did not recur within 60 weeks of excision with those that recurred.
  • METHODS: Cytologic specimens obtained from spontaneous BCCs from 11 dogs were analyzed by computerized nuclear morphometry.
  • Neoplastic cells from BCCs that subsequently recurred had higher MNA (102.41 +/- 4.57 microm(2)), MNP (36.27 +/- 0.61 microm), and MND (11.21 +/- 0.27 microm) than cells from nonrecurrent BCCs (MNA 87.66 +/- 4.79 microm(2), MNP 33.51 +/- 0.78 microm, MND 10.36 +/- 0.29 microm) (P<.001; Mann-Whitney U-test).
  • CONCLUSION: Based on these preliminary results, nuclear morphometry may be a useful tool to predict local recurrence of BCCs in dogs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet Clin Pathol. 2010 Jun;39(2):133; author reply 133-4 [20624263.001]
  • (PMID = 19645743.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Stoebner PE, Le Gallic L, Berthe ML, Boulle N, Lallemant B, Marque M, Gaspard C, Delfour C, Lavabre-Bertrand T, Martinez J, Meunier L: Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas. Exp Dermatol; 2008 Nov;17(11):908-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
  • Thymidine phosphorylase (TP)/platelet-derived endothelial cell growth factor is associated with tumor angiogenesis.
  • We evaluated the TP mRNA and protein expression in basal cell carcinomas (BCC) and in various skin tumors including numerous BCC histological simulants.
  • Immunohistochemistry was performed on 99 paraffin sections of formalin-fixed skin tumors using monoclonal antibodies (mAb) against TP.
  • TP mRNA levels were measured by real time RT-PCR in whole BCCs (wBCC) and laser capture microdissected (LCM) BCC tumor cells.
  • TP immunostaining was negative in all BCC variants and in most of the benign trichogeneic tumors studied.
  • By contrast, TP was constantly immunodetected in actinic keratosis (AK), squamous cell carcinomas (SCC), syringomatous carcinomas (SC), basosquamous carcinomas (BSC) and melanomas.
  • TP mRNA levels were low and statistically not different in wBCC and normal skin but were strongly downregulated in LCM-BCC as compared with LCM-normal epidermis.
  • We concluded that (i) anti-TP mAb is an useful marker to differentiate BCC from AK, SCC, BSC and SC but not from trichoblastic tumors, (ii) the lack of TP protein expression in BCC tumoral cells is linked to transcriptional regulatory mechanisms, (iii) the low TP mRNA levels in whole BCC may be related to the low intra-tumoral microvessel density, the slow growth and the very low metastatic potential of these tumors.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Thymidine Phosphorylase / genetics
  • [MeSH-minor] Carcinoma, Basosquamous / genetics. Carcinoma, Basosquamous / metabolism. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratosis, Actinic / genetics. Keratosis, Actinic / metabolism. Keratosis, Actinic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341568.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


13. Betti R, Menni S, Radaelli G, Bombonato C, Crosti C: Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J Dermatol; 2010 Jul;37(7):611-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas.
  • Micronodular basal cell carcinoma (BCC) may be more difficult to eradicate and prone to recurrence than nodular subtype.
  • The aim of the study was to compare anatomical and histological characteristics of the basal cell carcinomas subtypes and the relationship of the micronodular BCC with other subtypes.
  • Primary BCCs (n = 3074) were classified as superficial, nodular, micronodular, morpheic/infiltrative.
  • Fifty-one micronodular BCCs were matched randomly with nodular and infiltrative cases, by age, sex, and tumor site.
  • Micronodular, nodular and infiltrative BCC were prevalently located in the head/neck (P < 0.0001), while superficial in the other regions (P < 0.0001).
  • The Clark level was comparable between micronodular and infiltrative BCC, while nodular BCC showed a more superficial level than micronodular (P < 0.001) and infiltrative (P < 0.001) BCC.
  • No nodular BCC had level IV and only 37.3% level III, while 92% of both micronodular and infiltrative BCC were level III or IV.
  • The percentage of level IV was 11.8% and 25.5% in micronodular and infiltrative BCC, respectively.
  • In the mid-face/periauricular region, 95.5% of micronodular and 100% of infiltrative cases of were level III or IV, compared to 50% of nodular BCC (P < 0.001).
  • The Clark level of nodular subtype was higher for BCC of mid-face/periauricular than other regions (P < 0.05).
  • It can be concluded that micronodular BCC shows intermediate characteristics compared with nodular and infiltrative subtypes but appears to have a specific individuality making it a distinct subtype.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Scalp / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629826.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Loncaster J, Swindell R, Slevin F, Sheridan L, Allan D, Allan E: Efficacy of photodynamic therapy as a treatment for Gorlin syndrome-related basal cell carcinomas. Clin Oncol (R Coll Radiol); 2009 Aug;21(6):502-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of photodynamic therapy as a treatment for Gorlin syndrome-related basal cell carcinomas.
  • AIMS: The management of the multiple basal cell carcinomas (BCCs) that develop throughout life of patients with Gorlin syndrome can be challenging.
  • Photodynamic therapy (PDT) is a simple, repeatable out-patient procedure, which is associated with minimal skin deterioration.
  • It is now routinely used to treat superficial sporadic BCCs, using a topically-applied photosensitiser and external light, but its role in the management of Gorlin syndrome-related BCCs has yet to be established.
  • The use of a systemic photosensitiser +/- interstitial light delivery extended the remit of PDT, allowing thicker lesions (>2 mm) to be treated, resulting in local control rates of 59.3% in this group.
  • PDT can be considered as a treatment option for patients with multiple BCCs as a result of Gorlin syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398312.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


15. Plaza JA, Ortega PF, Bengana C, Stockman DL, Suster S: Immunolabeling pattern of podoplanin (d2-40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases. Am J Dermatopathol; 2010 Oct;32(7):683-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolabeling pattern of podoplanin (d2-40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases.
  • When the morphologic distinction between basal cell carcinomas (BCCs) and tichoepitheliomas is unclear, it poses a rare diagnostic challenge as the commonly defined histologic criterion is insufficient for differentiating these two neoplasms from each other.
  • Their distinction is clinically important because the risk of progressive disease in BCC can be problematic, and trichoepitheliomas misinterpreted as BCC burdens the patient with an inaccurate diagnosis and consequential inappropriate surgery.
  • Podoplanin (D2-40) is a well-known lymphatic endothelial surface marker that has been postulated to be upregulated in the outer root sheath of hair follicles and cutaneous neoplasms, such as adnexal tumors, squamous cell carcinomas, etc.
  • A total of 49 cutaneous tumors, including 22 cases of trichoepitheliomas and 27 cases of BCC were examined.
  • Of the 27 cases of BCC, 18 cases were located in the head and neck area, 5 on upper extremities, and 4 on the back.
  • Of the 22 cases of trichoepitheliomas, all were from the head and neck area.
  • D2-40 expression was present in 21/22 cases of trichoepitheliomas; 11 cases were diffusely positive (50%), 10 cases were focally positive (45.5%), and 1 case was negative (4.5%).
  • D2-40 expression was present in 6/27 cases of BCC; 2 cases were diffusely positive (7.4%), 4 cases were focally positive (14.8%), and 21 cases were negative (77.8%).
  • In summary, D2-40 expression was only weakly and focally positive in BCC (22.2% of cases) and diffusely and weakly positive in trichoepitheliomas (95.5% of cases).
  • The sensitivity and specificity of D2-40 immunoreactivity to separate trichoepitheliomas from BCCs was 95.5% and 77.8%, respectively.
  • This data suggests that D2-40 expression could be a useful potential marker to distinguish BCCs from trichoepitheliomas, especially when there is a high index of histologic suspicion for either of these two tumors.
  • Our results also suggest that BCC can show differentiation toward the outer root sheath of hair follicles.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Membrane Glycoproteins / biosynthesis. Neoplasms, Basal Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal. Antibodies, Monoclonal, Murine-Derived. Diagnosis, Differential. Humans. Immunohistochemistry. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20559122.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / monoclonal antibody D2-40
  •  go-up   go-down


16. Gorin MA, Iniesta MD, Douglas JA, Milliron KJ, Merajver SD: Absence of the CHEK2*1100delC mutation in non-BRCA1/2 families with multiple cancer types in a high-risk clinic population of Caucasian ancestry. J Clin Oncol; 2009 May 20;27(15_suppl):11040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of the CHEK2*1100delC mutation in non-BRCA1/2 families with multiple cancer types in a high-risk clinic population of Caucasian ancestry.
  • : 11040 Background: Checkpoint kinase 2(CHEK2) is a cell-cycle-checkpoint kinase that phosphorylates p53 and BRCA1 in response to DNA damage.
  • The contribution of CHEK2 mutations to familial cancer has been widely studied in breast cancer.
  • Most notably, the CHEK2*1100delC mutation has been characterized to confer a 2-fold increased risk for breast cancer in carriers.
  • This finding comes from studies performed on Northern and Eastern European populations.
  • In contrast to the work done in Europe, these studies suggest a lower frequency of CHEK2*1100delC mutations in breast cancer families.
  • The aim of this study was to determine the frequency of CHEK2*1100delC in members of breast cancer families who tested negative for a deleterious mutation in BRCA1/2.
  • Families were characterized by the presence of several cases of breast and/or ovarian cancer and multiple members with other cancers in a single lineage.
  • RESULTS: No CHEK2*1100delC mutations were detected in 115 individuals, including 39 women diagnosed with breast cancer at an early age, 7 women with bilateral cancer, 2 men with breast cancer and 6 women with ovarian cancer, all of whom were negative for mutations in BRCA1/2.The CHEK2 Breast Cancer Consortium previously reported a frequency of 2.3% for the CHEK2*1100delC mutation among breast cancer cases from families with at least 2 cases of breast cancer (or breast and ovarian cancer) in a first- or second-degree relationship.
  • CONCLUSIONS: Our data are consistent with previous reports that suggest a lower frequency of CHEK2*1100delC mutations in North American hereditary breast cancer families without BRCA1/2 mutations and enriched for multiple cancer types.
  • The low frequency of the CHEK2*1100delC in the North American population limits its clinical relevance as a cancer predisposing gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Olsson H, Attner B, Noreen D, Lithman T: Comorbidity prior to diagnosis in patients with common cancer diagnoses. J Clin Oncol; 2009 May 20;27(15_suppl):e22180

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity prior to diagnosis in patients with common cancer diagnoses.
  • : e22180 Background: Chronic disease as diabetes, hypertonia and anemia may be associated with cancer risk as well as affect the short term survival of the malignancy.
  • METHODS: Using population based registry data from specialist and primary care in our health care region comorbidity in the form of anemia, hypertonia, diabetes, rheumatoid arthritis, chronic obstructive pulmonary diasease (KOL), and alcohol related diseases for patients with colon-, rectal-, lung-, prostate and breast cancer and survival were studied.
  • Altogether 2047 colon cancer cases, 985 rectal cancer cases, 2017 lung cancer cases, 3578 breast cancer cases and 5106 prostate cancer cases diagnosed 2000-2005 were included.
  • Comorbidity was studied prior to cancer diagnosis and in order to compare with the general population all first comorbidity diagnoses within 90 days were censored.
  • Patients with colon and rectal cancer had a higher prevalence of anemia, and diabetes.
  • Patients with lung cancer had a higher prevalence of anemia, KOL, diabetes, rheumatoid arthritis for both men and women and for men also a higher prevalence of alcohol related diseases.
  • Except for alcohol related diseases in females with breast cancer comorbidity for the above diseases was not significantly elevated for breast or prostate cancer.
  • Survival of the different cancer diagnoses was not significantly related to the comorbidity except for a tendency of worse survival for patients with alcohol related disease.
  • CONCLUSIONS: The prevalence of some common chronic diseases are elevated especially in colon-, rectal and lung cancer patients.
  • The comorbidity does not seem to affect short term survival of the cancer patient except for alcohol related diagnoses.
  • Our study also indicates the necessity to have all levels of care included in the study base of comorbidity and also emphasizes the need to censor time prior to diagnosis when comparing data with the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963595.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Iturbe J Jr, Zwenger A, Lacava JA, Perez Verdera P, Vallejo C, Romero A, Leone JP, Perez J, Maccihavelli M, Leone B: Treatment of early breast cancer (EBC): A long-term follow-up study-GOCS experience. J Clin Oncol; 2009 May 20;27(15_suppl):e11610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of early breast cancer (EBC): A long-term follow-up study-GOCS experience.
  • : e11610 Background: Most cases of breast cancer are diagnosed at early stage of disease, therefore treatment is oriented to increase the relapse-free survival (RFS) and overall survival (OS).
  • RFS was analyzed from the date of initial diagnosis to the date of local or distant recurrence.
  • OS was estimated from the date of initial diagnosis to the last follow-up or date of death.
  • Adjuvant radiation therapy was administered to 73% of pts, whereas adjuvant chemotherapy to 29% and adjuvant hormone therapy to 18.5% of cases.
  • Local recurrence was documented in 37 pts (3.8%) whereas 269 developed metastatic disease (29%).
  • Bilateral breast cancer was seen in 102 cases (10.9%) and 91 pts (9.7%) developed 2nd malignancies.
  • This group of pts continues to have a good prognosis as shown by the OS rate at 5, 10, 15, 20 and 25 years, although high percentage of pts continue to have recurrence and die from breast cancer after 5, 10, 15, 20 and 25 years of follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961127.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Jones CA, Adams M: Re: "Laterality of periocular basal cell carcinomas in relation to driving practices in Philadelphia, PA, U.S.A.". Ophthal Plast Reconstr Surg; 2007 May-Jun;23(3):252-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: "Laterality of periocular basal cell carcinomas in relation to driving practices in Philadelphia, PA, U.S.A.".
  • [MeSH-major] Automobile Driving. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Functional Laterality. Neoplasms, Radiation-Induced / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthal Plast Reconstr Surg. 2011 Jul-Aug;27(4):306 [21057343.001]
  • [CommentOn] Ophthal Plast Reconstr Surg. 2007 May-Jun;23(3):252 [17519678.001]
  • (PMID = 17519677.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


20. Toll A, Parera ME, Vélez M, Pujol RM: Letter: photodynamic therapy with methyl aminolevulinate induces phototoxic reactions on areas of the nose adjacent to basal cell carcinomas and actinic keratoses. Dermatol Surg; 2008 Aug;34(8):1145-7; discussion 1147-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter: photodynamic therapy with methyl aminolevulinate induces phototoxic reactions on areas of the nose adjacent to basal cell carcinomas and actinic keratoses.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Dermatitis, Phototoxic / etiology. Keratosis / drug therapy. Nose Neoplasms / drug therapy. Photochemotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518890.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


21. Hall L, Struijk L, Neale RE, Feltkamp MC: Re: Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst; 2006 Oct 4;98(19):1425-6
MedlinePlus Health Information. consumer health - Sun Exposure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin.
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / virology. Papillomaviridae. Papillomavirus Infections / complications. Skin Neoplasms / virology. Sunburn / complications. Tumor Virus Infections / complications

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • (PMID = 17018790.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


22. Kaune KM, Haas E, Buhl T, Schön MP, Zutt M: Multiple basal cell carcinomas arising in radiotherapy-treated nevus flammeus: early detection facilitated by 595-nm pulsed dye laser. Eur J Dermatol; 2010 Jul-Aug;20(4):510-1
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple basal cell carcinomas arising in radiotherapy-treated nevus flammeus: early detection facilitated by 595-nm pulsed dye laser.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Lasers, Dye / therapeutic use. Low-Level Light Therapy. Port-Wine Stain / radiotherapy. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Thorax

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403798.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


23. Santiago Sánchez-Mateos D, Goiriz Valdés R, Daudén Tello E: Multiple basal cell carcinomas after radiation treatment: successful treatment with topical imiquimod. Clin Exp Dermatol; 2010 Mar;35(2):199-200
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple basal cell carcinomas after radiation treatment: successful treatment with topical imiquimod.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Neoplasms, Radiation-Induced / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486047.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


24. Vidal D, Matías-Guiu X, Alomar A: Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol; 2007 Feb;143(2):266-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17310012.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


25. Alpsoy E, Durusoy C, Ozbilim G, Karpuzoğlu G, Yilmaz E: Nevus comedonicus syndrome: a case associated with multiple basal cell carcinomas and a rudimentary toe. Int J Dermatol; 2005 Jun;44(6):499-501
Hazardous Substances Data Bank. BENZOYL PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nevus comedonicus syndrome: a case associated with multiple basal cell carcinomas and a rudimentary toe.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Nevus, Pigmented / diagnosis. Skin Neoplasms / diagnosis. Toes / abnormalities

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941441.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 5688UTC01R / Tretinoin; 74469-00-4 / Amoxicillin-Potassium Clavulanate Combination; W9WZN9A0GM / Benzoyl Peroxide
  •  go-up   go-down


26. Hiraldo A, Gómez-Moyano E, Martínez S, Sanz A: [Melanomas and basal cell carcinomas in a patient with Parkinson disease]. Actas Dermosifiliogr; 2010 Jan-Feb;101(1):95-6
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Melanomas and basal cell carcinomas in a patient with Parkinson disease].
  • [Transliterated title] Melanomas y carcinomas basocelulares en un paciente con enfermedad de Parkinson.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Melanoma / complications. Neoplasms, Multiple Primary / complications. Parkinson Disease / complications. Skin Neoplasms / complications
  • [MeSH-minor] Adult. Antiparkinson Agents / adverse effects. Antiparkinson Agents / therapeutic use. Disease Susceptibility. Dopamine / biosynthesis. Dopamine Agonists / adverse effects. Dopamine Agonists / therapeutic use. Humans. Levodopa / adverse effects. Levodopa / therapeutic use. Male. Melanins / biosynthesis

  • Genetic Alliance. consumer health - Parkinson Disease.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20109402.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 0 / Dopamine Agonists; 0 / Melanins; 46627O600J / Levodopa; VTD58H1Z2X / Dopamine
  •  go-up   go-down


27. Ríos-Buceta L: [Management of basal cell carcinomas with positive margins]. Actas Dermosifiliogr; 2007 Dec;98(10):679-87
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of basal cell carcinomas with positive margins].
  • A common problem in day-to-day practice is the approach to take following resection of basal cell carcinoma with positive margins.
  • In such cases, it is important to decide whether we should take a wait-and-see approach or consider re-excision or radiotherapy.
  • To make this decision, 4 key points need to be clarified: the significance of positive margins; whether positive margins are equivalent to tumor persistence; whether negative margins equate with complete excision; and the rate of recurrence in cases of re-excision compared in those in which a wait and see approach is taken.
  • Having addressed each of these points, the approach will depend on the characteristics of the individual case.
  • Based on the evidence presented, an aggressive approach involving re-excision would seem indicated in aggressive cases, whereas a flexible strategy combining observation, surgery, and radiotherapy (or other treatments) can be used in less aggressive cases.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035025.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 39
  •  go-up   go-down


28. Wuest M, Dummer R, Urosevic M: Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod. Arch Dermatol Res; 2007 Dec;299(10):493-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod.
  • Basal cell carcinoma of the skin (BCC) is the most common skin tumor in Caucasians worldwide.
  • Different therapeutic options are available to treat BCC, including topical immunotherapy.
  • Imiquimod is topical Toll-like receptor 7 agonist that activates anti-tumor immune response and has been recently approved for the treatment of superficial BCC (sBCC).
  • We sought to investigate the influence of imiquimod treatment on the members of the Notch signaling pathway, whose activity is known to be decreased in BCCs.
  • [MeSH-major] Aminoquinolines / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma, Basal Cell / drug therapy. Signal Transduction / drug effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922128.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Calcium-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; 0 / delta protein; 134324-36-0 / Serrate proteins; 99011-02-6 / imiquimod
  •  go-up   go-down


29. Macpherson N, Lamrock E, Watt G: Effect of inflammation on positive margins of basal cell carcinomas. Australas J Dermatol; 2010 May;51(2):95-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of inflammation on positive margins of basal cell carcinomas.
  • BACKGROUND/OBJECTIVES: The use of preparations such as imiquimod in the treatment of basal cell carcinoma is well accepted.
  • METHOD: A retrospective audit was carried out on basal cell carcinoma removed in the Dermatology Clinic of the Royal Newcastle Centre in 2007.
  • These were the location of the basal cell carcinoma excision and the excision type.
  • CONCLUSION: The study has shown the majority of negative re-excisions were from lesions on the head which had had an initial surgical procedure.
  • A larger sample size that encompassed all three factors that affect outcome, that is, the location of lesion, type of lesion and type of excision carried out, would be required in order to make a more definitive statement on protocol change for treatment of basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546214.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


30. Betti R, Radaelli G, Bombonato C, Crosti C, Cerri A, Menni S: Anatomic location of Basal cell carcinomas may favor certain histologic subtypes. J Cutan Med Surg; 2010 Nov-Dec;14(6):298-302
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomic location of Basal cell carcinomas may favor certain histologic subtypes.
  • BACKGROUND: Differences in age, site, and subtype exist in basal cell carcinoma (BCC).
  • OBJECTIVE: To evaluate whether an independent association exists between the anatomic location and the histologic subtype of BCC.
  • MATERIALS AND METHODS: A series of 3,254 BCCs was examined.
  • RESULTS: Prevalence of BCCs on the head/neck or chest/abdomen increased with age (p < .001).
  • The prevalence of superficial subtype was lower among BCCs on the head/neck than other locations (24.9% vs 64.4%, OR 0.18, 95% CI 0.16-0.21).
  • The prevalence of nodular or morpheic/infiltrative subtype was higher among BCCs on the head/neck than other locations, that is, 57.1% versus 29.2%, OR 3.23, 95% CI 2.79 to 3.74 (nodular) and 16.1% versus 4.0%, OR 4.56, 95% CI 3.42 to 6.08 (morpheic/infiltrative).
  • CONCLUSION: Anatomic location and subtype of BCC were associated with age, but the anatomic location was the only independent predictor of histologic subtype.
  • Although a bias by referral patterns may not be excluded, the results suggest that the anatomic location may favor the development of particular BCC subtypes.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084023.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Kiiski V, de Vries E, Flohil SC, Bijl MJ, Hofman A, Stricker BH, Nijsten T: Risk factors for single and multiple basal cell carcinomas. Arch Dermatol; 2010 Aug;146(8):848-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for single and multiple basal cell carcinomas.
  • OBJECTIVE: To investigate the incidence of single and multiple basal cell carcinoma (BCC) lesions and associated risk factors.
  • PATIENTS: Patients with BCC lesions were identified from the Dutch national pathology laboratories network, hospitals, and general practices.
  • MAIN OUTCOME MEASURES: The associations between determinants and single and multiple BCC lesions were studied by estimating odds ratios (ORs) and hazards ratios, using multivariate logistic regression and Andersen-Gill models, respectively.
  • RESULTS: Of the eligible 10 820 cohort members, 524 (4.8%) had BCC, of whom 361 had single and 163 (31.1%) had multiple lesions.
  • Age and red hair were significant risk factors for a first BCC lesion in a multivariate model.
  • In the Andersen-Gill model, people who developed a first BCC lesion after 75.0 years of age were significantly less likely to develop multiple lesions (> or =75.0 years adjusted OR, 0.58; 95% confidence interval [CI], 0.47-0.71).
  • Red hair (adjusted OR, 1.43; 95% CI, 1.05-1.94), high educational level (1.42; 1.12-1.81), and a first BCC lesion located on the upper extremities (1.49; 1.02-2.15) were associated with a significantly increased risk of developing multiple lesions.
  • CONCLUSION: Patients who are relatively young at their first BCC diagnosis, those with red hair, those with higher socioeconomic status, and/or those with a BCC lesion on their upper extremities have a higher risk of developing multiple lesions and require closer follow-up over time.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Neoplasms, Multiple Primary / epidemiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20713815.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Mc Loone NM, Tolland J, Walsh M, Dolan OM: Follow-up of basal cell carcinomas: an audit of current practice. J Eur Acad Dermatol Venereol; 2006 Jul;20(6):698-701
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of basal cell carcinomas: an audit of current practice.
  • BACKGROUND: Follow-up of patients after treatment of basal cell carcinoma (BCC) allows for monitoring of recurrence and detection of new tumours, but adds a significant burden to outpatient clinics.
  • At the skin tumour clinic in the dermatology department, the Royal Hospitals, Belfast, all patients are reviewed for 2 years after surgical excision of a low-risk primary BCC.
  • OBJECTIVES: An audit was undertaken to determine the quality of data set recorded relating to prognostic factors for BCCs to determine the rate of recurrence and number of new primary tumours detected and to determine the completeness of follow-up by patients.
  • METHOD: Patients who had primary BCCs treated by excision were identified from a database held at the clinic.
  • Medical charts were reviewed to determine data recorded about lesions, the number of recurrent BCCs and new tumours detected, and the number of patients completing follow-up.
  • RESULTS: Between January 1999 and December 2000, 114 patients had 121 primary BCCs excised.
  • BCC location and size were recorded in 100% and 35% of cases, respectively.
  • The rate of recurrence was low, with 2 BCC recurring within 2 years of excision.
  • The risk of developing a new BCC was 11.6% in the first year and 6.3% in the second year.
  • CONCLUSIONS: Follow-up of patients after excision of a low-risk BCC at the clinic has been reduced to 1 year.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Guideline Adherence. Practice Guidelines as Topic. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Male. Medical Audit. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / epidemiology. Practice Patterns, Physicians' / statistics & numerical data. Prognosis. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16836498.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Dixon A: Micronodular basal cell carcinomas. Aust Fam Physician; 2006 Dec;35(12):965-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micronodular basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Facial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17149470.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


34. Yu M, Zloty D, Cowan B, Shapiro J, Haegert A, Bell RH, Warshawski L, Carr N, McElwee KJ: Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J Invest Dermatol; 2008 Jul;128(7):1797-805
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles.
  • Basal-cell carcinoma (BCC), the most common neoplasm in humans, occurs in a variety of morphological presentations.
  • The mechanisms of BCC development downstream of the initial genetic mutations are not well understood, and different BCC morphological presentations might exhibit distinct gene expression patterns.
  • We investigated superficial (n=8), nodular (n=8), and morpheiform (n=7) BCCs using 21K cDNA microarrays.
  • Global gene expression profiles between respective BCC subtypes, and as compared with normal skin (n=8), were statistically defined by significance analysis of microarrays (SAM).
  • Thirty-seven genes were subsequently validated by quantitative reverse transcriptase-PCR analysis using an expanded set of 31 BCCs.
  • Gene ontology analysis indicated that gene expression patterns of BCC subtypes in multiple biological processes showed significant variation, particularly in genes associated with the mitogen-activated protein kinase (MAPK) pathway.
  • Notably, genes involved in response to DNA-damage stimulus were uniquely upregulated in morpheiform BCCs.
  • Our results indicate a relative similarity in gene expression between nodular and superficial BCC subtypes.
  • In contrast, morpheiform BCCs are more diverse, with gene expression patterns consistent with their more "invasive" phenotype.
  • These data may help us understand the complex behavior of BCC subtypes and may eventually lead to new therapeutic strategies.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Gene Expression Profiling. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Cyclooxygenase 2 / genetics. Disease Progression. Epithelium / metabolism. Female. Humans. MAP Kinase Signaling System. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Signal Transduction. Skin / metabolism. Wnt Proteins / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18200053.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


35. Lally A, Charnock F, Clelland C, Turner R, Wojnarowska F: Multiple vulval basal cell carcinomas. J Eur Acad Dermatol Venereol; 2007 Mar;21(3):407-8
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple vulval basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Humans. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309477.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


36. Araco A, Gravante G, Araco F, Delogu D, Cervelli V: Giant basal cell carcinomas. Plast Reconstr Surg; 2006 Sep;118(3):818-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Neoplasm Invasiveness. Skin Ulcer / etiology. Skin Ulcer / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Plast Reconstr Surg. 2006 Jan;117(1):6e-9e [16404239.001]
  • (PMID = 16932215.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


37. Tan WP, Tan AW, Ee HL, Kumarasinghe P, Tan SH: Melanization in basal cell carcinomas: microscopic characterization of clinically pigmented and non-pigmented tumours. Australas J Dermatol; 2008 Nov;49(4):202-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanization in basal cell carcinomas: microscopic characterization of clinically pigmented and non-pigmented tumours.
  • Clinical and microscopic pigmentation may affect the treatment outcomes in basal cell carcinoma.
  • However, there have not been any in-depth histopathological comparisons between clinically pigmented and non-pigmented basal cell carcinomas with regards to microscopic melanization.
  • The aims of our study were to determine the proportion of pigmented basal cell carcinomas presenting to the National Skin Centre in Singapore, to characterize the histological pattern of melanization and to perform a semi-quantitative analysis of the degree of microscopic melanization of the tumours.
  • Patients with clinical features and histologically confirmed basal cell carcinomas were recruited.
  • Demographic data and clinical characteristics were recorded and basal cell carcinoma sections were examined for histological subtype and pattern of melanization.
  • Twenty-five Chinese patients with 30 basal cell carcinomas were recruited.
  • Three of the five clinically non-pigmented and all of the clinically pigmented basal cell carcinomas had microscopic evidence of melanization.
  • Microscopic melanization in clinically non-pigmented basal cell carcinomas was present only focally or in the centre of the tumour mass.
  • Both groups of basal cell carcinomas may be colonized by melanocytes.
  • Two morphological types of melanocytes, a dendritic and round cell type, were identified.
  • Future research is required to evaluate if the degree of microscopic melanization influences the treatment outcome of basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanocytes / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Melanins. Middle Aged. Prospective Studies. Skin Pigmentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855781.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Melanins
  •  go-up   go-down


38. Booth CM, Li G, Mackillop WJ: The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: A population-based study in Ontario, Canada. J Clin Oncol; 2009 May 20;27(15_suppl):6505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of socioeconomic status (SES) on stage of cancer at time of diagnosis: A population-based study in Ontario, Canada.
  • : 6505 Background: Lower SES is known to be associated with worsened cancer survival.
  • Here we evaluate the impact of SES on stage of cancer at diagnosis in Ontario which has universal health insurance.
  • METHODS: All incident cases of breast, colon, rectal, non-small cell lung, cervical and larynx cancer diagnosed in Ontario 2003-2005 were identified using the Ontario Cancer Registry.
  • Stage information is only captured routinely for patients seen at Ontario's 8 Regional Cancer Centers (RCCs).
  • Using a best stage grouping approach, cases were assigned stage based on pathologic TNM if available and clinical TNM otherwise.
  • Using postal code at time of diagnosis cases were assigned to quintiles (Q); Q1 represents the communities where the poorest 20% of the Ontario population resided.
  • RESULTS: Stage at diagnosis was available for 19,239/23,254 (83%) of cases seen at RCCs.
  • Among cases with breast cancer, those in Q1 were less likely to have stage I disease (43 vs 47%, p = 0.004) and more likely to have stage IV disease (5 vs 4%, 0.008) than Q2-5.
  • With lung cancer, cases in Q1 were more likely to have stage I disease compared to Q2-5 (16 vs 13%, p = 0.015).
  • Distribution of stage I and stage IV disease did not differ by SES across other individual diseases.
  • However, for all 6 cancers combined, cases in Q1 were less likely than Q2-5 to have stage I disease (27 vs 30%, p = 0.001) and more likely to have stage IV disease (21 vs 18%, p < 0.0001).
  • We found significant gradients in 3-year overall survival across Q1-Q5 for breast (5% absolute difference in survival, p < 0.001), colon (4%, p = 0.049), and cervical (18%, p = 0.031) cancers.
  • CONCLUSIONS: Despite universal health care, SES remains associated with survival among patients with cancer in Ontario.
  • These data suggest that the difference in outcome is only partially explained by differences in stage at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Maiti B, Kundranda MN, Jin T, Spiro TP, Daw HA: The association of metabolic syndrome with triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of metabolic syndrome with triple-negative breast cancer.
  • : 1038 Background: Metabolic syndrome, a conglomerate of obesity, insulin resistance, hypertriglyceridemia, low HDL (high density lipoprotein), and hypertension is associated with an increased risk of breast cancer.
  • However, no clear association has been shown between the highly aggressive triple-negative breast cancer and metabolic syndrome.
  • METHODS: In a retrospective review we compared triple-negative and non-triple-negative breast cancer cases for the presence of metabolic syndrome by NCEP (National Cholesterol Education Program) or AACE (American Association of Clinical Endocrinologists) definitions.
  • Data on metabolic syndrome criteria, tumor size, grade, lymph node status, and ductal carcinoma in situ (DCIS) were reviewed.
  • RESULTS: The entire cohort of 176 patients (12.5% African-American) with median age 56.5 years (range 26-91 years) comprised of 86 triple-negative cases and 90 non-triple-negative cases.
  • A statistically significant association of triple-negative breast cancer with metabolic syndrome was observed.
  • Contrary to blood glucose, triglyceride, or HDL levels, which independently showed significant association with triple-negative breast cancer, hypertension, or BMI showed no independent association.
  • Additionally, triple-negative tumors displayed a significantly higher histologic grade and relative paucity of ductal carcinoma in situ (DCIS) when compared to the non-triple negative tumors (p < 0.001).
  • CONCLUSIONS: The data suggests that the metabolic syndrome is significantly more prevalent in triple-negative breast cancer patients when compared to the non-triple-negative patients.
  • Additionally, triple-negative breast cancer showed a significantly higher histologic grade and a relative absence of DCIS.
  • Whether the presence of metabolic syndrome preferentially increases the risk of developing triple-negative-breast cancer needs to be elucidated by future prospective studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Malik V, Goh KS, Leong S, Tan A, Downey D, O'Donovan D: Risk and outcome analysis of 1832 consecutively excised basal cell carcinomas in a tertiary referral plastic surgery unit. J Plast Reconstr Aesthet Surg; 2010 Dec;63(12):2057-63
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk and outcome analysis of 1832 consecutively excised basal cell carcinomas in a tertiary referral plastic surgery unit.
  • BACKGROUND: Basal cell carcinomas are the most prevalent of all skin cancers worldwide and form the majority of the surgical workload for most modern cutaneous malignancy centres.
  • Primary surgical removal of basal cell carcinomas remains the gold standard of treatment but, despite almost two centuries of surgical experience, rates of incomplete surgical excision of up to 50% are still reported.
  • The aim of this study was to assess, quantify and perform comparative analysis of the outcomes and predictive factors of consecutive primarily-excised basal cell carcinomas in a tertiary centre over a six-year period.
  • METHODS: Retrospective audit was conducted on all patients who underwent surgical excision of basal cell carcinomas from January 2000 to December 2005.
  • RESULTS: One thousand eight hundred and thirty two basal cell carcinomas were excised from 1329 patients over the designated time period.
  • CONCLUSIONS: Overall basal cell carcinomas excision rates compared favourably with international reported standards but attention to a variety of surgical and histological risk factors may improve this further.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20226750.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


41. Allali J, D'Hermies F, Renard G: Basal cell carcinomas of the eyelids. Ophthalmologica; 2005 Mar-Apr;219(2):57-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas of the eyelids.
  • Basal cell carcinomas (BCC) are the more frequent malignant tumors seen in France as in other western countries.
  • Due to their local growth, problems may arise when treating BCC, and curative exeresis must be the preferred choice each time it is possible.
  • BCC of the eyelids have a high risk of recurrence.
  • Eyelid reconstructions can entail use of complex methods which should only be carried out by a trained ophthalmologist who is also able to treat any associated age-related ocular pathologies.
  • BCC is the most common cause leading to eyelid reconstructive surgery; a surgery which has a triple objective: tumor removal, functionality and an esthetic outcome.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Incidence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15802929.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 141
  •  go-up   go-down


42. Visram H, Dent SF: Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center. J Clin Oncol; 2009 May 20;27(15_suppl):e11613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center.
  • : e11613 Background: Male breast cancer (BC) comprises approximately 1% of all breast cancer cases, and over 80% of male BC tumours express the estrogen receptor (ER).
  • METHODS: We conducted a retrospective chart review of 24 pts diagnosed with male BC at the Ottawa Regional Cancer Centre from 1986-2003.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Arias Santiago SA, Girón Prieto MS, Aneiros Fernández J, Burkhardt Pérez P, Naranjo Sintes R: [Descriptive analysis of basal cell carcinomas in patients aged more than 65 years old undergoing surgery in Hospital Clinic in Granada (Spain) in 2007]. Rev Esp Geriatr Gerontol; 2009 Mar-Apr;44(2):114-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Descriptive analysis of basal cell carcinomas in patients aged more than 65 years old undergoing surgery in Hospital Clinic in Granada (Spain) in 2007].
  • [Transliterated title] Análisis descriptivo de carcinomas basocelulares en pacientes mayores de 65 años intervenidos en el Hospital Clínico de Granada en el año 2007.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19389545.001).
  • [ISSN] 0211-139X
  • [Journal-full-title] Revista española de geriatría y gerontología
  • [ISO-abbreviation] Rev Esp Geriatr Gerontol
  • [Language] spa
  • [Publication-type] Letter
  • [Publication-country] Spain
  •  go-up   go-down


44. Bagazgoitia L, Bea S, Santiago JL, Cuevas J, Juarranz A, Jaén P: Multiple basal cell carcinomas arising on a thermal-burn scar. Successful treatment with photodynamic therapy. J Eur Acad Dermatol Venereol; 2009 Apr;23(4):459-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple basal cell carcinomas arising on a thermal-burn scar. Successful treatment with photodynamic therapy.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18624869.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Konishi A, Sakai R, Ohta M, Fujii H, Moriwaki S, Horiguchi Y: Multiple basal cell carcinomas on the lateral neck linearly arranged along the lines of Blaschko occurring 50 years after X-ray radiation therapy for lymphadenitis coli tuberculosa. J Dermatol; 2008 Oct;35(10):680-2
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple basal cell carcinomas on the lateral neck linearly arranged along the lines of Blaschko occurring 50 years after X-ray radiation therapy for lymphadenitis coli tuberculosa.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Neck / radiation effects. Neoplasms, Radiation-Induced / pathology. Tuberculosis, Lymph Node / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017051.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  •  go-up   go-down


46. Ferreres JR, Macaya A, Jucglà A, Muniesa C, Prats C, Peyrí J: Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol; 2006 Aug;20(7):877-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Basal Cell Nevus Syndrome / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898919.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


47. Saponaro AE, Marini MA, Rossi GC, Casas JG: Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1. Int J Dermatol; 2006 Jan;45(1):87-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / pathology. Myotonic Dystrophy / complications. Myotonic Dystrophy / pathology. Skin Neoplasms / complications. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Myotonic dystrophy.
  • Genetic Alliance. consumer health - Myotonic dystrophy type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426388.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


48. Clarke JT, Fulchiero GJ Jr, Jones CR, Clarke L, Billingsley EM: A "triple hit": basal cell carcinomas arising in an organ transplant recipient after venipunctures in irradiated skin. Dermatol Surg; 2008 Oct;34(10):1417-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A "triple hit": basal cell carcinomas arising in an organ transplant recipient after venipunctures in irradiated skin.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Heart Transplantation. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Punctures / adverse effects. Radiotherapy / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Bone Neoplasms / radiotherapy. Forearm. Humans. Male. Sarcoma, Ewing / radiotherapy. Skin / pathology

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657164.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


49. Epstein EH, Shepard JA, Flotte TJ: Case records of the Massachusetts General Hospital. Case 3-2008. An 80-year-old woman with cutaneous basal-cell carcinomas and cysts of the jaws. N Engl J Med; 2008 Jan 24;358(4):393-401
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case records of the Massachusetts General Hospital. Case 3-2008. An 80-year-old woman with cutaneous basal-cell carcinomas and cysts of the jaws.
  • [MeSH-major] Basal Cell Nevus Syndrome / diagnosis. Carcinoma, Basal Cell / pathology. Odontogenic Cysts / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Skull / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18216361.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Martín JM, Monteagudo C, Alonso V, Llombart B, de la Fuente C, García L, Jordá E: Basal cell carcinomas arising on a skin graft secondary to a thermal burn scar. Burns; 2005 Sep;31(6):789-91
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas arising on a skin graft secondary to a thermal burn scar.
  • [MeSH-major] Burns / complications. Carcinoma, Basal Cell / etiology. Cicatrix / surgery. Skin Neoplasms / etiology. Skin Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985336.001).
  • [ISSN] 0305-4179
  • [Journal-full-title] Burns : journal of the International Society for Burn Injuries
  • [ISO-abbreviation] Burns
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Chan SY, Madan V, Lear JT, Helbert M: Highly active antiretroviral therapy-induced regression of basal cell carcinomas in a patient with acquired immunodeficiency and Gorlin syndrome. Br J Dermatol; 2006 Nov;155(5):1079-80
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy-induced regression of basal cell carcinomas in a patient with acquired immunodeficiency and Gorlin syndrome.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antiretroviral Therapy, Highly Active. Basal Cell Nevus Syndrome / complications
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Regression, Spontaneous. Treatment Outcome


52. Chapas AM, Gilchrest BA: Broad area photodynamic therapy for treatment of multiple basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome. J Drugs Dermatol; 2006 Feb;5(2 Suppl):3-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Broad area photodynamic therapy for treatment of multiple basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome.
  • We report a case of a 73-year-old man with nevoid basal cell carcinoma syndrome who was referred to us with multiple basal cell carcinomas on his face and chest.
  • This treatment strategy resulted in multiple benefits, including reducing the number and size of his existing basal cell carcinomas, improving the appearance of previous surgical scars, and decreasing the rate of tumor development.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • Genetic Alliance. consumer health - Basal Cell Carcinoma, Multiple.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485873.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


53. Piesold JU, Vent S, Krüger R, Pistner H: [Treatment results after surgery for basal cell carcinomas of the head and neck region taking into consideration various reconstruction techniques]. Mund Kiefer Gesichtschir; 2005 May;9(3):143-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results after surgery for basal cell carcinomas of the head and neck region taking into consideration various reconstruction techniques].
  • BACKGROUND: Basal cell carcinomas are the most frequently occurring malignant tumors in the white population.
  • PATIENTS AND METHOD: All cases of basal cell carcinoma treated at the department for oral and maxillofacial and regional plastic surgery of the HELIOS hospital in Erfurt between 1976 and 2003 were analyzed and partly reexamined in a retrospective study.
  • RESULTS: A total of 648 patients with 765 basal cell carcinomas were treated.
  • In 64% of the cases the basal cell carcinomas were nodular, in 16% infiltrative.
  • DISCUSSION: If an infiltrative basal cell carcinoma is suspected or insufficient radical primary surgery is presumed, plastic reconstruction should be postponed until free margins can be confirmed histologically.
  • The functional and aesthetic quality of reconstruction was better using pedicled flaps (90%) and primary closure (86%) than using free skin transplants (30-54%).
  • Nevertheless, free skin flaps and epitheses were found to be well accepted by the reexamined patients.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasms, Radiation-Induced / surgery. Skin Neoplasms / surgery. Sunlight / adverse effects
  • [MeSH-minor] Aged. Dermatologic Surgical Procedures. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Orbit Evisceration. Outcome and Process Assessment (Health Care). Retrospective Studies. Skin / pathology. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15719264.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Yayli S, Akyazi H, Bahadir S, Alpay K, Cobanoğlu U: Coexistence of basal cell carcinomas and multiple sebaceous gland hyperplasias in a cyclosporine (ciclosporin)-treated renal transplant recipient. Am J Clin Dermatol; 2010;11(1):59-62
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of basal cell carcinomas and multiple sebaceous gland hyperplasias in a cyclosporine (ciclosporin)-treated renal transplant recipient.
  • A biopsy from the asymptomatic, yellowish papule on the face showed sebaceous gland hyperplasia, and biopsies from the lesions on the nose revealed basal cell carcinomas.
  • Sebaceous gland hyperplasia and skin cancers are among the cutaneous neoplasms observed in renal transplant recipients receiving cyclosporine.
  • To our knowledge, this is the third reported case of the coexistence of basal cell carcinomas and multiple sebaceous gland hyperplasias in a cyclosporine-treated renal transplant recipient.
  • [MeSH-major] Carcinoma, Basal Cell / chemically induced. Cyclosporine / adverse effects. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Sebaceous Gland Diseases / chemically induced. Skin Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20000877.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


55. Heyl J, Mehregan D: Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J Cutan Pathol; 2008 Jan;35(1):40-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas.
  • BACKGROUND: Distinction between sebaceous tumors and basal cell carcinomas can often pose diagnostic problems.
  • Our aim was to evaluate the use of CK 19 staining patterns in differentiating between sebaceous tumors and basal cell carcinomas.
  • The sebaceous tumors that were examined in this study included sebaceous adenomas, sebaceous epitheliomas (sebaceomas) and sebaceous carcinomas.
  • METHODS: Thirty-seven cases including 5 sebaceous adenomas, 16 sebaceous epitheliomas, 6 sebaceous carcinomas and 14 basal cell carcinomas (7 being of the morpheaform type and 7 nodular basal cell carcinomas) were tested with a monoclonal mouse antibody to human CK 19.
  • RESULTS: CK 19 was focally positive in 1/5 (20%) sebaceous adenomas, 8/16 (50%) of sebaceous epitheliomas and 1/6 (17%) of sebaceous carcinomas.
  • Strongly positive expression of CK 19 was not seen in any of the sebaceous adenoma, sebaceous epithelioma or sebaceous carcinoma specimens.
  • CK 19 was found to be strongly positive in 9/14 (64%) and focally positive in 2/14 (14%) of basal cell carcinomas.
  • CONCLUSION: CK 19 expression can be helpful in differentiating sebaceous tumors (including sebaceous adenomas, sebaceous epitheliomas and sebaceous carcinomas) from basal cell carcinomas and may be a useful adjunct when these entities are included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Keratin-19 / analysis. Sebaceous Gland Neoplasms / diagnosis. Sebaceous Glands / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095993.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19
  •  go-up   go-down


56. Rieger UM, Schlecker C, Pierer G, Haug M: Spontaneous regression of two giant basal cell carcinomas in a single patient after incomplete excision. Tumori; 2009 Mar-Apr;95(2):258-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of two giant basal cell carcinomas in a single patient after incomplete excision.
  • BACKGROUND: Spontaneous regression of small basal cell carcinoma has been reported.
  • For giant basal cell carcinoma, however, no spontaneous regression has been described to date.
  • CASE REPORT: We present a patient with two independent giant basal cell carcinomas over the left clavicle and the lower back, measuring 7 x 12 cm and 18 x 20 cm, respectively.
  • CONCLUSION; Incompletely excised giant basal cell carcinomas can regress spontaneously.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Materia Medica / therapeutic use. Neoplasm Regression, Spontaneous. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Back. Clavicle / pathology. Humans. Lumbar Vertebrae / pathology. Male. Neoplasm Invasiveness. Spinal Neoplasms / secondary. Wound Healing / drug effects

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579878.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Materia Medica
  • [Number-of-references] 51
  •  go-up   go-down


57. Eisner JM, Russell M: Cartilage hair hypoplasia and multiple basal cell carcinomas. J Am Acad Dermatol; 2006 Feb;54(2 Suppl):S8-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cartilage hair hypoplasia and multiple basal cell carcinomas.
  • An increased incidence of malignancy has been reported in this condition, but basal cell carcinoma and CHH has not previously been reported in the dermatology literature.
  • We report the case of a 25-year-old woman with CHH and multiple basal cell carcinomas.
  • A causal relationship is conceivable and, therefore, for patients with CHH, dermatologists should be aware of a possible increased risk of basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Hair / pathology. Immunologic Deficiency Syndromes / complications. Osteochondrodysplasias / complications. Skin Neoplasms / complications

  • Genetic Alliance. consumer health - Cartilage-Hair Hypoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428006.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Lane JE, Allen JH, Lane TN, Lesher JL Jr: Unilateral Basal cell carcinomas: an unusual entity treated with photodynamic therapy. J Cutan Med Surg; 2005 Dec;9(6):336-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral Basal cell carcinomas: an unusual entity treated with photodynamic therapy.
  • BACKGROUND: Unilateral localized basal cell carcinomas are an uncommon finding that presents both a diagnostic and therapeutic challenge.
  • Exclusion of unilateral nevoid basal cell carcinoma syndrome is indicated.
  • OBJECTIVE: We present a patient with unilateral localized basal cell carcinomas who was successfully treated with photodynamic therapy.
  • The patient had an excellent therapeutic response with no clinically apparent basal cell carcinomas for 18 months.
  • CONCLUSIONS: We report a patient with unilateral basal cell carcinomas successfully treated with photodynamic therapy.
  • This uncommon entity represents a diagnostic challenge in its inherent absence of the classic clinical and radiographic findings of nevoid basal cell carcinoma syndrome.
  • Like nevoid basal cell carcinoma syndrome, unilateral basal cell carcinomas poses a therapeutic challenge with the sheer number of cutaneous tumors.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Basal Cell Nevus Syndrome / diagnosis. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699902.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


59. Natkunarajah J, Cliff S: Thorium X treatment: multiple basal cell carcinomas within a port-wine stain. Clin Exp Dermatol; 2009 Jul;34(5):e189-91
Hazardous Substances Data Bank. THORIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thorium X treatment: multiple basal cell carcinomas within a port-wine stain.
  • We report a 64-year-old man with a history of multiple basal cell carcinomas in a facial port wine stain, which had previously been treated with thorium X.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Facial Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Port-Wine Stain / radiotherapy. Radium / adverse effects. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077098.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 13233-32-4 / thorium X; 60YU5MIG9W / Thorium; W90AYD6R3Q / Radium
  •  go-up   go-down


60. Schütt F, Staff C, Stein T, Hartschuh W, Dithmar S: [Photodynamic therapy of lid basal cell carcinomas in a 13-year-old patient with Gorlin Goltz syndrome]. Klin Monbl Augenheilkd; 2007 Aug;224(8):670-3
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photodynamic therapy of lid basal cell carcinomas in a 13-year-old patient with Gorlin Goltz syndrome].
  • BACKGROUND: Gorlin Goltz syndrome is a rare, autosomal dominant inherited disease that is characterised by multiple basal cell carcinomas (BCC) including the periorbital region and eye lids.
  • PATIENT: A 13-year-old boy with Gorlin Goltz syndrome presented with multiple confluent BCC on both eye lids and the skin of neck and trunk.
  • Multiple bilateral periorbital confluent and surgically not removable BCC were treated by topical PDT.
  • RESULTS: Numerous superficial BCC were successfully treated by photodynamic therapy with remarkable cosmetic results.
  • CONCLUSION: In cases of numerous confluent and surgically not removable BCC, PDT represents an effective therapy.
  • [MeSH-major] Basal Cell Nevus Syndrome / drug therapy. Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / drug therapy. Eyelid Neoplasms / pathology. Photochemotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717785.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Madan V, West CA, Murphy JV, Lear JT: Sequential treatment of giant basal cell carcinomas. J Plast Reconstr Aesthet Surg; 2009 Oct;62(10):e368-72
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential treatment of giant basal cell carcinomas.
  • Treatment of giant basal cell carcinomas (GBCC) can pose several challenges.
  • In such instances, use of routine and recommended treatments for sporadic, average size basal cell carcinomas (BCC) is suboptimal, impractical and often leads to treatment failure.
  • While individually, photodynamic therapy, topical imiquimod and surgical excision are all established treatments for BCC, their combined use in the treatment of GBCC has not been explored.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18572004.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod
  •  go-up   go-down


62. Rybka MO, Cintra ML, de Souza EM, Metze K: Density of dendritic cells around basal cell carcinomas is related to tumor size, anatomical site and stromal characteristics, and might be responsible for the response to topical therapy. Int J Dermatol; 2008 Dec;47(12):1240-4
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Density of dendritic cells around basal cell carcinomas is related to tumor size, anatomical site and stromal characteristics, and might be responsible for the response to topical therapy.
  • BACKGROUND: The dermal dendritic cell (DC) is considered to be an important component of the host defense against basal cell carcinomas (BCCs).
  • Imiquimod, an immunologic response modifier, has recently been introduced in the topical therapy of BCCs.
  • The aim of our study was to find out which clinical or histological variables are related to the DC density at the margins of BCCs.
  • METHODS: Thirty cases of BCCs of aggressive and 30 cases of nonaggressive subtypes were selected from our files.
  • For the aggressive subtypes, a higher DC density was related not only to an increased myofibroblast density, smaller BCCs or location on the face, but also to the presence of less mucinous and more granulation type stroma and an increased DC density in the normal dermis.
  • CONCLUSION: Our study demonstrates that the density of DCs around BCCs is related to tumor size, localization and characteristics of the surrounding tumor stroma.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / pathology. Langerhans Cells / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Cell Count. Facial Neoplasms / drug therapy. Facial Neoplasms / pathology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126008.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


63. Flohil SC, de Vries E, van Meurs JB, Fang Y, Stricker BH, Uitterlinden AG, Nijsten T: Vitamin D-binding protein polymorphisms are not associated with development of (multiple) basal cell carcinomas. Exp Dermatol; 2010 Dec;19(12):1103-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D-binding protein polymorphisms are not associated with development of (multiple) basal cell carcinomas.
  • Vitamin D-binding protein (VDBP) single nucleotide polymorphisms (SNP) may affect skin carcinogenesis.
  • The objective was to test the association between two functional VDBP SNPs and the susceptibility to (multiple) basal cell carcinomas (BCCs).
  • Two hundred and thirty-three persons developed a BCC of whom 122 (52.4%) developed multiple BCCs during a mean follow-up of 11.6 years.
  • The VDBP genotype was not associated with (multiple) BCC development using Cox proportional hazards and Andersen-Gill analyses, respectively.
  • Stratifying age groups demonstrated that in the youngest age-group, the A/T variant of rs7041 was associated with BCC development [adjusted hazard ratio (HR) = 1.88 (95%CI 1.10-3.20)], while homozygote Gc1s carriers had a significantly lower BCC risk [adjusted HR = 0.53 (95%CI 0.31-0.91)].
  • In conclusion, the VDBP polymorphisms were not associated with susceptibility to (multiple) BCCs, but age-gene interactions were observed.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Polymorphism, Single Nucleotide / genetics. Vitamin D-Binding Protein / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20812960.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Vitamin D-Binding Protein
  •  go-up   go-down


64. Oseroff AR, Shieh S, Frawley NP, Cheney R, Blumenson LE, Pivnick EK, Bellnier DA: Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol; 2005 Jan;141(1):60-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy.
  • OBJECTIVE: To report the use of wide-area 5-aminolevulinic acid photodynamic therapy to treat numerous basal cell carcinomas (BCCs) and basaloid follicular hamartomas (BFHs).
  • DESIGN: Report of cases.
  • SETTING: Roswell Park Cancer Institute.
  • Patients Three children with BCCs and BFHs involving 12% to 25% of their body surface areas.
  • Conclusion 5-Aminolevulinic acid photodynamic therapy is safe, well tolerated, and effective for extensive areas of diffuse BCCs and BFHs and appears to be the treatment of choice in children.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Basal Cell Nevus Syndrome / drug therapy. Hamartoma Syndrome, Multiple / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655143.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / P01-CA55791
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


65. Whitaker IS, Shokrollahi K, James W, Mishra A, Lohana P, Murison MC: Combined CO(2) laser with photodynamic therapy for the treatment of nodular basal cell carcinomas. Ann Plast Surg; 2007 Nov;59(5):484-8
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined CO(2) laser with photodynamic therapy for the treatment of nodular basal cell carcinomas.
  • BACKGROUND: Basal cell carcinomas (BCC) are often seen by plastic surgeons and dermatologists in the outpatient setting.
  • Treatment usually necessitates excision of these lesions with an appropriate margin guided by published recommendations, often resulting in less than ideal cosmetic outcomes, especially if local flaps or skin grafts are required for reconstruction.
  • Photodynamic therapy (PDT) and CO(2) laser when used as monotherapy have been successfully used to treat BCCs, with greatest success in the superficial histologic subtype.
  • These modalities when used alone have a number of limitations when compared with surgical excision, including a limited depth of penetration of PDT (2-mm absorption), which potentially limits the efficacy of treatment of nodular BCCs greater than this thickness or which are deeply invasive.
  • METHODS: Twelve patients with 13 biopsy-proven nodular BCCs on the head and neck were treated with combined therapy using an Ultra Pulse CO(2) and PDT using Methyl Aminolevulinate (METVIX) and the Aktilite 16 LED lamp.
  • The only complications encountered were mild hypopigmentation in 2 cases and mild discomfort experienced with PDT.
  • CONCLUSION: In this study, CO(2) laser and PDT appear to play a synergistic role in the treatment of nodular basal cell carcinomas.
  • [MeSH-major] Carbon Dioxide / chemistry. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Basal Cell / therapy. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / therapy. Lasers. Photochemotherapy / methods. Skin Neoplasms / radiotherapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992139.001).
  • [ISSN] 0148-7043
  • [Journal-full-title] Annals of plastic surgery
  • [ISO-abbreviation] Ann Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


66. Santiago F, Serra D, Vieira R, Figueiredo A: Incidence and factors associated with recurrence after incomplete excision of basal cell carcinomas: a study of 90 cases. J Eur Acad Dermatol Venereol; 2010 Dec;24(12):1421-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and factors associated with recurrence after incomplete excision of basal cell carcinomas: a study of 90 cases.
  • BACKGROUND: Management of incompletely excised basal cell carcinomas (BCC) remains controversial.
  • OBJECTIVE: The aim of this study was to assess the rate and the factors associated with the recurrence of incompletely excised BCC.
  • METHODS: In this retrospective monocentric study, data from all surgically excised BCC during 4 years (2000 to 2003) were analysed.
  • RESULTS: A total of 947 BCC were excised.
  • Recurrence of incompletely excised BCC was significantly higher (P < 0.05) in younger patients, in aggressive histological types and in localizations like postauricular and nasogenian folds.
  • CONCLUSION: Observation might be an acceptable option in many situations, but for patients with aggressive types of BCC, or with tumours localized in risk areas of the face, immediate re-excision appears to be the treatment of choice.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20384689.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


67. Rogalski C, Kauer F, Simon JC, Paasch U: Meta-analysis of published data on incompletely excised basal cell carcinomas of the ear and nose with introduction of an innovative treatment strategy. J Dtsch Dermatol Ges; 2007 Feb;5(2):118-26
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of published data on incompletely excised basal cell carcinomas of the ear and nose with introduction of an innovative treatment strategy.
  • BACKGROUND: Auricular/nasal basal cell carcinomas (BCC) often require more surgical procedures than BCCs at other sites.
  • METHODS: A meta-analysis of incompletely excised BCCs compares those on the ear and nose to other sites.
  • The combination of photodynamic diagnostics (PDD) and fresh-frozen sections is compared to multi-stage excisions; in each case, the tissue margins were histographically controlled.
  • RESULTS: The relative risk of an incomplete excision of a BCC on the ear/nose is 2.5 fold higher than on the rest of the body.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / therapy. Mohs Surgery / statistics & numerical data. Photochemotherapy / statistics & numerical data. Skin Neoplasms / epidemiology. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Dtsch Dermatol Ges. 2007 Jun;5(6):541
  • (PMID = 17274778.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Germany
  •  go-up   go-down


68. Berman B: Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas. J Drugs Dermatol; 2008 Jan;7(1 Suppl 1):s3-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scientific rationale: combining imiquimod and surgical treatments for basal cell carcinomas.
  • The number of basal cell carcinomas (BCCs) occurring in the US in 2007 has been conservatively estimated to be 1 million.
  • Surgical extirpation alone is the standard for the treatment for BCCs, which results in scarring and is associated with recurrences.
  • We review the rationale for combining surgical extirpation and immunotherapy with topically applied imiquimod 5% cream for the treatment of BCCs.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277456.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 14
  •  go-up   go-down


69. Short MA, Lui H, McLean D, Zeng H, Alajlan A, Chen XK: Changes in nuclei and peritumoral collagen within nodular basal cell carcinomas via confocal micro-Raman spectroscopy. J Biomed Opt; 2006 May-Jun;11(3):34004
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in nuclei and peritumoral collagen within nodular basal cell carcinomas via confocal micro-Raman spectroscopy.
  • Confocal micro-Raman spectroscopy is used to probe the nuclei of normal human epidermal cells and epidermally derived cancer cells from nodular basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Collagen / analysis. Microscopy, Confocal / instrumentation. Spectrum Analysis, Raman / instrumentation
  • [MeSH-minor] Equipment Design. Equipment Failure Analysis. Humans. Reproducibility of Results. Sensitivity and Specificity. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16822054.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


70. Kozyreva ON, Konnikov N: The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e14646

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy.
  • : e14646 Background: Non-melanoma skin cancer (NMSC) is the most common form of human cancer.
  • RESULTS: 43 Caucasian males (range 59- 87 yrs), 37 (87%) had history of NMSC on the face or scalp, 32 (78%) had basal cell carcinoma (BCC), 11 (22%) squamous cell carcinoma (SCC), 100% of patients had multiple (>4) AKs prior to treatment and 23 (75% ) had moderate to severe DH determined by Griffiths scale.
  • Prior to ALA-PDT 74 NMSC's were documented: 40 (54%) BCC and 34 (46%) SCC.
  • 46 NMSC's were documented following ALA-PDT: 22 (48%) BCC and 24 (52%) SCC.
  • Prior to ALA-PDT, the frequency of BCC averaged 2 [IQR 1 to 3, max=4], and the frequency of SCC averaged 1 [IQR 1 to 1, max=3].
  • Following ALA-PDT, the occurrence of BCC averaged 1 [IQR 0 to 1, max=5], and that of SCC averaged 1 [IQR 0 to 2, max= 4].
  • The difference between BCC frequency before and after ALA-PDT treatment shown a significant reduction in BCC incidence (P = 0.0018).
  • No such differences were observed between the frequency of SCC before and after ALA-PDT (P=0.6230) Conclusions: A single ALA-PDT treatment to the face or scalp in high risk patients significantly reduces the incidence of BCC, the incidence of SCC was not reduced.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC: Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis; 2010 Jun;85(6):318-24
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
  • We conducted a prospective, multicenter, phase 3, open-label study to assess long-term sustained clearance of superficial basal cell carcinomas (sBCCs) treated with imiquimod cream 5%.
  • Tumor recurrence, serious adverse events (AEs), local skin reactions (LSRs), and skin quality assessments (SQAs) were measured.
  • Local skin reactions and application site reactions, the AEs reported by the most participants, occurred predominantly during the treatment period and resolved posttreatment.
  • Compared to baseline, investigator-assessed SQA scores for the target tumor site improved for skin surface abnormalities and hyperpigmentation, and worsened for hypopigmentation.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666194.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


72. Wiedemeyer K, Hartschuh W: Trichoblastomas with Merkel cell proliferation in nevi sebacei in Schimmelpenning-Feuerstein-Mims syndrome--histological differentiation between trichoblastomas and basal cell carcinomas. J Dtsch Dermatol Ges; 2009 Jul;7(7):612-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichoblastomas with Merkel cell proliferation in nevi sebacei in Schimmelpenning-Feuerstein-Mims syndrome--histological differentiation between trichoblastomas and basal cell carcinomas.
  • It represents a rare congenital nevus syndrome with alterations of skin, bones, CNS, eyes and heart.
  • Nevi sebacei can proliferate and develop into epithelial tumors like trichoblastoma, syringocystadenoma and basal cell carcinoma.
  • The histological differentiation between basal cell carcinoma and trichoblastoma is difficult.
  • We present an adult woman with SFMS who was followed by multiple specialties since birth without the correct diagnosis being made.
  • She was referred to us with the diagnosis of multiple basal cell carcinomas of head and face.
  • Our diagnosis of systematized nevus sebaceus was crucial for the correct classification of SFMS.
  • We identified multiple trichoblastomas in the nevi sebacei and could exclude basal cell carcinomas.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Merkel Cells / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / pathology. Cell Proliferation. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192012.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. Urosevic M, Kempf W, Zagrodnik B, Panizzon R, Burg G, Dummer R: HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy. Clin Exp Dermatol; 2005 Jul;30(4):422-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy.
  • Basal cell carcinoma (BCC) of the skin represents the most common malignancy in the fair-skinned population worldwide.
  • To investigate the role of HLA-G in recurring BCCs, we constructed a tissue microarray containing 38 primary BCCs that underwent radiotherapy and 14 secondary BCCs recurring on the primary site after radiotherapy, and evaluated the HLA-G protein expression by immunohistochemistry.
  • The HLA-G protein was most frequently expressed in aggressive sclerosing BCCs.
  • Nodular BCC demonstrated the strongest HLA-G expression.
  • Interestingly, tumor infiltrating mononuclear cells (TIMC) expressed the HLA-G molecule in BCCs that showed no recurrence.
  • After comparing primary BCCs and BCCs relapsed after radiotherapy, we observed decreased HLA-G expression on tumor cells and the loss of HLA-G expression on TIMC in relapsed BCCs.
  • After radiotherapy, immunobiology of BCC may change resulting in the down-regulation of HLA-G expression on tumor and on tumor-infiltrating cells.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. HLA Antigens / metabolism. Histocompatibility Antigens Class I / metabolism. Neoplasm Recurrence, Local / immunology. Skin Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953086.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


74. Scheibe P, Braumann UD, Kuska JP, Löffler M, Simon JC, Paasch U, Wetzig T: Image-processing chain for a three-dimensional reconstruction of basal cell carcinomas. Exp Dermatol; 2010 Jul 1;19(7):689-91
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-processing chain for a three-dimensional reconstruction of basal cell carcinomas.
  • Basal cell carcinoma (BCC) is the most common malignant skin cancer.
  • For a deeper insight into the specific growth patterns of the tumorous tissue in BCC, we have focused on the development of a novel automated image-processing chain for 3D reconstruction of BCC using histopathological serial sections.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Imaging, Three-Dimensional / methods. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted / methods. Neoplasm Invasiveness / pathology. Software Design

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20545759.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Denmark
  •  go-up   go-down


75. Heitzer E, Lassacher A, Quehenberger F, Kerl H, Wolf P: UV fingerprints predominate in the PTCH mutation spectra of basal cell carcinomas independent of clinical phenotype. J Invest Dermatol; 2007 Dec;127(12):2872-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UV fingerprints predominate in the PTCH mutation spectra of basal cell carcinomas independent of clinical phenotype.
  • Basal cell carcinoma (BCC) shows a wide interpatient variation in lesion accrual.
  • To determine whether certain tumorigenic fingerprints and potentially predisposing patched (PTCH) tumor suppressor single-nucleotide polymorphisms (SNPs) are distributed differently among sporadic BCC patients, we compared the PTCH mutation spectra in early-onset BCC (first lesion at age < 35 years), regular BCC (first lesion at age > or = 35 years and < 10 lesions), and multiple BCC (> or = 10 lesions).
  • The PTCH gene was mutated in 29 of 60 cases (48%).
  • Interestingly, expression of the IVS16-80G/C and the IVS17+21G/A genotype did not achieve the Hardy-Weinberg equilibrium in patients with regular and/or early-onset BCC.
  • These data suggest that a (UV-) mutated PTCH gene is important for sporadic BCC formation independent of clinical phenotype and that the IVS16-80G/C and/or IVS17+21G/A SNP site might be important for tumorigenesis in certain BCC patients.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / metabolism. DNA Mutational Analysis. Gene Expression Regulation, Neoplastic. Mutation. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics. Skin Neoplasms / metabolism. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597822.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


76. Badri T, Zeglaoui F, Kochbati L, Kooli H, El Fekih N, Fazaa B, Kamoun MR: [Multiple basal cell carcinomas following radiation therapy for nasopharyngeal cancer]. Presse Med; 2006 Jan;35(1 Pt 1):55-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple basal cell carcinomas following radiation therapy for nasopharyngeal cancer].
  • [Transliterated title] Carcinomes basocellulaires multiples après radiothérapie pour cancer du cavum.
  • INTRODUCTION: Basal cell carcinoma (BCC) is a cutaneous, generally primary malignancy, most common among the elderly.
  • We report the case of a patient presenting numerous BCCs several years after radiation therapy for nasopharyngeal cancer and discuss the risk factors for this tumor and the role played by radiation in its genesis.
  • CASE: A 30-year-old woman presented with pigmented facial lesions that had been developing over the past year.
  • Eleven years earlier, she had had an undifferentiated nasopharyngeal carcinoma (T3N2M0), which was treated by neoadjuvant chemotherapy and then external radiation therapy.
  • Initial cutaneous examination noted two lesions that were identified as BCC after biopsy.
  • Neither clinical nor radiological check up showed signs of basal cell nevus syndrome.
  • DISCUSSION: BCC is the most frequent malignant tumor.
  • Disorders that might promote or complicate BCC should be systematically sought in young patients, especially basal cell nevus syndrome.
  • The occurrence of BCC within the irradiation area, the multiplicity of lesions, and the sufficient latency period are consistent with radiation-induced tumors.
  • We found no reports in the literature of BCC following radiation treatment for nasopharyngeal cancer, but the occurrence of these tumors in our patient suggests the need for close supervision in such cases.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Multiple Primary / etiology. Neoplasms, Radiation-Induced / etiology. Radiotherapy / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Nasopharynx / pathology. Neoplasm Staging. Radiotherapy Dosage. Skin / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462665.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


77. Demirtaşoglu M, Ilknur T, Lebe B, Kuşku E, Akarsu S, Ozkan S: Evaluation of dermoscopic and histopathologic features and their correlations in pigmented basal cell carcinomas. J Eur Acad Dermatol Venereol; 2006 Sep;20(8):916-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of dermoscopic and histopathologic features and their correlations in pigmented basal cell carcinomas.
  • BACKGROUND: Because of their clinical similarities, pigmented basal cell carcinomas (BCCs) can be confused with melanocytic pigmented lesions especially with melanoma.
  • Since special dermoscopic features have been described for pigmented BCCs, dermoscopy is accepted as a useful tool for the diagnosis of pigmented BCCs.
  • OBJECTIVE: To investigate dermoscopic and corresponding histopathologic features of BCCs and to evaluate their correlations in pigmented BCCs.
  • METHODS: In this study, 32 pigmented BCCs in 30 patients whose diagnoses were confirmed with clinical and histopathologic features were included.
  • Histopathologic correlations of dermoscopic features of BCCs and the localization of pigment accumulation in tumour mass were investigated.
  • Whitish veil, which is among dermoscopic features of BCCs, did not show significant correlation with its histopathologic counterpart (P > 0.05).
  • CONCLUSIONS: Ulceration, large grey-blue ovoid nests, multiple grey-blue globules, maple leaf-like areas and arborizing telangiectasia, which are specific dermoscopic features for the diagnosis of pigmented BCC, were found to correlate with their histopathologic counterparts.
  • In conclusion, dermoscopy can be described as a valuable tool for the diagnosis of pigmented basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922937.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


78. Wallace DL, Jaffe W: Reply to 'Do basal cell carcinomas recur after complete conventional surgical excision? R.W. Griffiths, S.K. Suvarna, J. Stone BJPS (2005);58, 795-805'. J Plast Reconstr Aesthet Surg; 2006;59(11):1247
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reply to 'Do basal cell carcinomas recur after complete conventional surgical excision? R.W. Griffiths, S.K. Suvarna, J. Stone BJPS (2005);58, 795-805'.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Neoplasm Recurrence, Local. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]
  • (PMID = 17046636.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


79. Reifenberger J, Wolter M, Knobbe CB, Köhler B, Schönicke A, Scharwächter C, Kumar K, Blaschke B, Ruzicka T, Reifenberger G: Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol; 2005 Jan;152(1):43-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.
  • BACKGROUND: Basal cell carcinoma (BCC) of the skin is the most common human cancer.
  • The genetic alterations underlying BCC development are only partly understood.
  • OBJECTIVES: To investigate further the molecular genetics of sporadic BCCs, we performed mutation analyses of 10 skin cancer-associated genes in 42 tumours.
  • SMOH mutations were identified in four of the 42 BCCs (10%) while two tumours demonstrated mutations in SUFUH, including one missense mutation and one silent mutation.
  • None of the BCCs showed LOH at markers flanking the SUFUH locus.
  • Seventeen BCCs (40%) carried TP53 mutations, with only three tumours showing evidence of biallelic TP53 inactivation.
  • TP53 mutations were present in BCCs with and without mutations in PTCH, SMOH or SUFUH.
  • CONCLUSIONS: Our data confirm the importance of PTCH, SMOH and TP53 mutations in the pathogenesis of sporadic BCCs.
  • SUFUH alterations are restricted to individual cases while the other investigated genes do not appear to be important targets for mutations in BCCs.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Mutation. Neoplasm Proteins / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis / methods. DNA, Neoplasm / genetics. Female. Genes, p53. Humans. Loss of Heterozygosity. Male. Membrane Proteins / genetics. Middle Aged. Molecular Sequence Data. Polymorphism, Single-Stranded Conformational. Receptors, Cell Surface. Receptors, G-Protein-Coupled / genetics. Repressor Proteins / genetics. Signal Transduction / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15656799.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Repressor Proteins; 0 / SMO protein, human; 0 / SUFU protein, human; 0 / patched receptors
  •  go-up   go-down


80. Bernard P, Dupuy A, Brun P, Sasko A, Duru G, Nicoloyannis N, Decuypere L, Grob JJ: [Therapeutic modalities and economic assessment in the treatment of superficial basal cell carcinomas and multiple actinic keratoses by French dermatologists]. Ann Dermatol Venereol; 2007 Jun-Jul;134(6-7):527-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic modalities and economic assessment in the treatment of superficial basal cell carcinomas and multiple actinic keratoses by French dermatologists].
  • [Transliterated title] Evaluation médico-économique de la prise en charge des carcinomes basocellulaires superficiels et des kératoses actiniques multiples par les dermatologues français.
  • INTRODUCTION: To date, no prospective studies have been conducted in France describing the management of actinic keratoses (AK) and superficial basal cell carcinomas (sBCC).
  • The therapeutic modalities, the physicians involved and the laboratory examinations during the 3 months following diagnosis were recorded prospectively.
  • RESULTS: 512 patients with sBCC (mean age: 69 years; sex-ratio M/F: 0.92) were included in the study. sBCC was isolated in 80% of cases, measured less than 2 cm in 90%, and was located on the head/neck in 51% and on the trunk in 37%.
  • Histological confirmation of diagnosis of BCC was obtained in 85% of cases.
  • Treatment comprised surgical excision in 70% of cases, cryotherapy in 13%, topical therapy in 7% and curettage/electrodessication in 4%.
  • Clinical follow-up was performed in 79% of cases.
  • AKs were located on the head/neck in 74% of cases and on the trunk in 6%.
  • Treatment consisted of cryotherapy in 92% of cases.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Carcinoma, Basal Cell / surgery. Health Care Costs. Photosensitivity Disorders / economics. Photosensitivity Disorders / therapy. Skin Neoplasms / economics. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17657178.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


81. Breuninger H: [Reader's letter concerning K. Kreutzer, B.Bonnekoh, I. Franke, H. Gollnick. Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (Photdyn 501): practical experiences in problem patients with actinic keratoses and basal cell carcinomas. JDDG 2004,12:992-999]. J Dtsch Dermatol Ges; 2005 May;3(5):397
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reader's letter concerning K. Kreutzer, B.Bonnekoh, I. Franke, H. Gollnick. Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (Photdyn 501): practical experiences in problem patients with actinic keratoses and basal cell carcinomas. JDDG 2004,12:992-999].
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy. Photosensitivity Disorders / drug therapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Dtsch Dermatol Ges. 2004 Dec;2(12):992-9 [16285312.001]
  • (PMID = 16372809.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Comment; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


82. Moehrle M, Breuninger H, Schippert W, Häfner HM: Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study. Dermatol Surg; 2010 Mar;36(3):428-30
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Mohs Surgery. Neoadjuvant Therapy. Nose Neoplasms / drug therapy. Nose Neoplasms / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Dermatol Surg. 2009 Jan;35(1):24-9 [19018814.001]
  • (PMID = 20402949.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


83. Garcia-Martin E, Idoipe M, Gil LM, Pueyo V, Alfaro J, Pablo LE, Zubiri ML, Fernandez J: Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas. J Ocul Pharmacol Ther; 2010 Aug;26(4):373-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas.
  • PURPOSE: To assess the efficacy and safety of nonsurgical treatment with imiquimod (IMQ) 5% cream in patients with periocular nodular basal cell carcinoma (BCC).
  • METHODS: Fifteen patients with clinical and histopathological diagnosis of nodular BCC on the eyelid were treated with IMQ 5% cream once daily, 5 days/week for 6 weeks.
  • CONCLUSIONS: IMQ therapy is effective for treating periocular BCCs with a cure rate similar to that of surgery.
  • IMQ is a useful alternative to surgery in patients with periocular BCCs when other therapies have failed or are not possible.
  • [MeSH-major] Aminoquinolines / administration & dosage. Aminoquinolines / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Carcinoma, Basal Cell / drug therapy. Eyelid Neoplasms / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698800.001).
  • [ISSN] 1557-7732
  • [Journal-full-title] Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • [ISO-abbreviation] J Ocul Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / carbomer; 99011-02-6 / imiquimod
  •  go-up   go-down


84. Mseddi M, Dammak A, Jellouli M, Ghorbel S, Bouassida S, Marrekchi S, Zahaf A, Turki H: [Profile of basal cell carcinomas of the scalp after radiotherapy for tinea capitis (about 63 cases)]. Rev Med Liege; 2006 Oct;61(10):724-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Profile of basal cell carcinomas of the scalp after radiotherapy for tinea capitis (about 63 cases)].
  • [Transliterated title] Profil des carcinomes basocellulaires du cuir chevelu secondaires a une radiothérapie pour teigne (a propos de 63 cas).
  • The induction of basal cell carcinoma (BCC) of the scalp by X-ray therapy for tinea capitis is well known.
  • The aim of the study was to specify the epidemiological, clinical and histological characteristics of this disease.
  • Fifty one men and 12 women with a total of 108 BCC of the scalp are reported (1.76 lesion per patient and 1.13 cm on average of diameter).
  • The mean age at the occurrence of the BCC was 45.5 years.
  • Thirty seven percent of BCC occurred on the occipital area; 28.7% were in the parietal site.
  • The most frequent clinical aspect was the nodular BCC (51%) and the cicatricial BCC (35%).
  • Histological study showed a nodular aspect in 74 % and pigmentation in 62% of cases.
  • It is concluded that BCC of the scalp following X-ray therapy for tinea capitis have some clinical and histological particularities.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Head and Neck Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Scalp. Skin Neoplasms / etiology. Tinea Capitis / radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17209506.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


85. Boyd S, Tolvanen K, Virolainen S, Kuivanen T, Kyllönen L, Saarialho-Kere U: Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls. Virchows Arch; 2008 Jan;452(1):83-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls.
  • Matrix metalloproteinases (MMPs) have an important role in the initiation, growth, and invasion of malignant tumors.
  • Basal cell cancer (BCC) is the most common human malignancy.
  • The risk of BCC is 10-16 times higher among organ transplant recipients compared with the nontransplanted population.
  • The aim of this study was to compare the expression of several MMPs and their tissue inhibitors (TIMPs) in BCCs from kidney transplant recipients and controls.
  • Expression of MMPs-1, -7, -8, -9, -10, -13, -26, and TIMPs-1 and -3 was evaluated by immunohistochemistry in 25 samples of BCC of kidney transplant recipients and 25 matched controls representing superficial and nodular subtypes.
  • No significant differences were detected in MMP expression of BCC tumor cells between immunocompetent and immunodeficient patients.
  • However, MMPs-1 and -9 and TIMP-1 were expressed more frequently in stromal macrophages in the BCCs of immunocompetent patients.
  • Our results suggest that abundant peritumoral expression of TIMP-1 in non-immunocompromised patients limits ECM degradation permissive for cancer cell migration.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Immunocompromised Host. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Skin Neoplasms / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18034264.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


86. Ohson K, DesGroseilliers JP, Weatherhead S, Weatherhead L: Imiquimod 5% cream use for the treatment of basal cell carcinomas in elderly patients, in long-term care facilities, not amenable to surgical or radiation therapy. J Cutan Med Surg; 2006 Jul-Aug;10(4):201-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream use for the treatment of basal cell carcinomas in elderly patients, in long-term care facilities, not amenable to surgical or radiation therapy.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234120.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; P1QW714R7M / imiquimod
  •  go-up   go-down


87. Lortscher DN, Sengelmann RD, Allen SB: Acrochordon-like basal cell carcinomas in patients with basal cell nevus syndrome. Dermatol Online J; 2007;13(2):21
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acrochordon-like basal cell carcinomas in patients with basal cell nevus syndrome.
  • Basal cell nevus syndrome is an autosomal dominant disorder characterized by multiple basal cell carcinomas, along with numerous other documented clinical features.
  • Acrochordons (or skin tags) are common benign neoplasms that are appropriately left untreated in most patients.
  • We describe two patients with known BCNS who were found to have multiple BCCs that clinically resembled acrochordons.
  • Our findings support the biopsy of acrochordon-like growths in patients with basal cell nevus syndrome to rule out basal cell carcinoma.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Cell Transformation, Neoplastic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Child. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Risk Assessment

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498440.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Liboutet M, Portela M, Delestaing G, Vilmer C, Dupin N, Gorin I, Saiag P, Lebbé C, Kerob D, Dubertret L, Grandchamp B, Basset-Seguin N, Soufir N: MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas. J Invest Dermatol; 2006 Jul;126(7):1510-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas.
  • In this study, we assessed the role of melanocortin 1 receptor (MC1R) variants and of two patched (PTCH) polymorphisms (c.3944C>T (P1315L), insertion 18 bp IVS1-83) as risk factors for basal cell carcinoma (BCC) in the French population.
  • The population investigated comprised 126 BCC patients who were enrolled on the basis of specific criteria (multiple and/or familial BCC and/or onset before the age of 40 years and/or association with another tumor)--and 151 controls matched for ethnicity, age, and sex.
  • MC1R variants appeared as a moderate risk factor for BCC (odds ratio (OR) for one and two variants, 2.17 [1.28-3.68] and 7.72 [3.42-17.38], respectively), independently of pigmentation characteristics (OR = 2.53 [1.34-4.8]).
  • Interestingly, in addition to the predictable red hair color (RHC) alleles, two non-RHC alleles (V60L and V92M) were also closely associated with BCC risk (OR 3.21 [1.91-5.38] and 2.87 [1.5-5.48], respectively), which differs from the situation in the Celtic population.
  • In addition, the PTCH c.3944C/C genotype was also associated with BCC risk (OR 1.94 [1.2-3.1]), especially in the subgroup of patients with multiple tumors (OR 2.16 [1.3-3.6]).
  • Thus, our data show that MC1R and PTCH variants are associated with BCC risk in the French population.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Polymorphism, Genetic. Receptor, Melanocortin, Type 1 / genetics. Receptors, Cell Surface / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. European Continental Ancestry Group / genetics. Female. France / ethnology. Gene Frequency. Genetic Predisposition to Disease. Hair Color. Humans. Male. Middle Aged. Odds Ratio. Prospective Studies. Regression Analysis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645598.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Melanocortin, Type 1; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


89. Paavilainen V, Tuominen J, Aho VV, Saari KM: Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland. Eur J Ophthalmol; 2007 Jul-Aug;17:494-500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland.
  • : . PURPOSE: Basal cell carcinoma (BCC) is the most common skin cancer of the eyelid, showing an increasing incidence in the white population.
  • The authors studied the clinical characteristics and the treatment results of BCC of the eyelid in southwestern Finland during 1977-1997.
  • METHODS: The authors reviewed the case records of 191 patients with BCC of the eyelids treated at the Turku University Eye Clinic during 1977-1997.
  • RESULTS: The 191 patients had altogether 194 BCC tumors of the eyelid with the mean diameter of the tumor being smaller than 10 mm in 77.3% of cases.
  • Of the 194 BCC tumors of the eyelid 16.0% showed recurrence, and the recurrence rate of all surgically treated tumors was 13.7%.
  • In this study 61 patients (31.9%) developed other malignancies than the BCC of the eyelid including 28 patients (14.7 %) with carcinoma in other locations than skin.
  • CONCLUSIONS: Incompletely removed BCCs of the eyelid showed only 18.9% recurrence rate during the follow-up time.
  • On the other hand, BCCs of the eyelid should not be underestimated because of the rather high total recurrence rate.
  • The frequency of 31.9% of other malignancies than BCC of the eyelid is remarkably high and requires special attention from the ophthalmologist taking care of the patient with BCC of the eyelid.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221540.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


90. Feito-Rodríguez M, Sendagorta-Cudós E, Moratinos-Martínez M, González-Beato MJ, de Lucas-Laguna R, Pizarro A: Dermatoscopic characteristics of acrochordon-like basal cell carcinomas in Gorlin-Goltz syndrome. J Am Acad Dermatol; 2009 May;60(5):857-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatoscopic characteristics of acrochordon-like basal cell carcinomas in Gorlin-Goltz syndrome.
  • BACKGROUND: Gorlin-Goltz syndrome (GGS) is an autosomal-dominant disease characterized by the early onset of multiple basal cell carcinomas (BCCs), among other findings.
  • Clinically, the BCCs may appear as soft pedunculated neoplasms that can be mistaken for true acrochordons.
  • OBJECTIVE: We sought to describe the dermatoscopic characteristics of small acrochordon-like or polypoid BCCs in a child with GGS, and to perform histopathologic correlation.
  • RESULTS: Some acrochordon-like lesions showed specific dermatoscopic criteria for BCC, including multiple blue-gray globules and arborizing telangiectasia.
  • Other polypoid lesions, especially the smaller ones, exhibited characteristics that suggested BCC, such as isolated blue-gray globules, small blue-gray ovoid nests, and fine elongated telangiectases.
  • CONCLUSION: Dermatoscopy may be a useful diagnostic tool to analyze acrochordon-like lesions in children and to facilitate early diagnosis and treatment of BCCs in patients with GGS.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233510.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Koseoglu RD, Sezer E, Eyibilen A, Aladag I, Etikan I: Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas. J Cutan Pathol; 2009 Sep;36(9):958-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expressions of p53, cyclinD1 and histopathological features in basal cell carcinomas.
  • BACKGROUND: We planned this study to analyze probable associations between p53, cyclinD1, Ki67 and histopathological features in basal cell carcinomas (BCC).
  • METHODS: Histological differentiation types, histological growth patterns and tissue responses were analyzed in 50 cases of BCC.
  • Besides, p53-positive cases showed more severe fibrosis and had a higher mean value for Ki67 index.
  • Epidermal p53 and cyclinD1 clones in normal epidermal areas adjacent to tumors were noticed in 42% and 52% of the cases, respectively.
  • CONCLUSIONS: P53 expression seems to be related to Ki67 index and some histopathological features of BCC, such as infiltrative histological growth pattern and probably fibrosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Cyclin D1 / biosynthesis. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187116.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


92. Gareau DS, Karen JK, Dusza SW, Tudisco M, Nehal KS, Rajadhyaksha M: Sensitivity and specificity for detecting basal cell carcinomas in Mohs excisions with confocal fluorescence mosaicing microscopy. J Biomed Opt; 2009 May-Jun;14(3):034012
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity for detecting basal cell carcinomas in Mohs excisions with confocal fluorescence mosaicing microscopy.
  • Recent studies have demonstrated the ability of confocal fluorescence mosaicing microscopy to rapidly detect basal cell carcinomas (BCCs) directly in thick and fresh Mohs surgical excisions.
  • Comparison of mosaics to Mohs frozen histopathology was shown to be excellent for all types of BCCs.
  • In this work, we report the results of a semiquantitative preclinical study in which 45 confocal mosaics are blindly evaluated for the presence (or absence) of BCC tumor.
  • BCCs are detected with an overall sensitivity of 96.6%, specificity of 89.2%, positive predictive value of 93.0%, and negative predictive value of 94.7%.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Microscopy, Confocal / methods. Microscopy, Fluorescence / methods. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • [Cites] J Cell Biol. 1985 Apr;100(4):1309-23 [3920227.001]
  • [Cites] J Microsc. 2009 Jan;233(1):149-59 [19196421.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • (PMID = 19566305.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NIBIB NIH HHS / EB / R01 EB002715; United States / NIBIB NIH HHS / EB / R01 EB002715-05; United States / NIBIB NIH HHS / EB / R01EB002715
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] F30N4O6XVV / Acridine Orange
  • [Other-IDs] NLM/ NIHMS95360; NLM/ PMC2705883
  •  go-up   go-down


93. Patel YG, Nehal KS, Aranda I, Li Y, Halpern AC, Rajadhyaksha M: Confocal reflectance mosaicing of basal cell carcinomas in Mohs surgical skin excisions. J Biomed Opt; 2007 May-Jun;12(3):034027
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal reflectance mosaicing of basal cell carcinomas in Mohs surgical skin excisions.
  • Precise removal of basal cell carcinomas (BCCs) with minimal damage to the surrounding normal skin is guided by the examination of frozen histology of each excision during Mohs surgery.
  • Confocal reflectance mosaicing may enable rapid detection of BCCs directly in surgical excisions, with minimal need for frozen histology.
  • Soaking the excisions in acetic acid rapidly brightens nuclei and enhances BCC-to-dermis contrast.
  • Clinically useful concentrations of acetic acid from 10 to 1% require 30 s to 5 min, respectively.
  • Compared to brightfield, cross-polarization enhances contrast and detectability of BCCs in the papillary dermis but not in the reticular dermis.
  • Comparison of mosaics to histology shows that nodular, micronodular, and superficial BCCs are easily detected.
  • However, infiltrative and sclerosing BCCs tend to be obscured within the surrounding bright dermis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Image Interpretation, Computer-Assisted / methods. Microscopy, Confocal / methods. Mohs Surgery / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Surgery, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614735.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01EB002715
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


94. Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC, Tada K, Ong WY, Soong R, Voon DC, Ito Y: RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene; 2006 Dec 7;25(58):7646-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX3 protein is overexpressed in human basal cell carcinomas.
  • Basal cell carcinomas (BCC), which are the most common form of skin malignancy, are invariably associated with the deregulation of the Sonic Hedgehog (Shh) signalling pathway.
  • As such, BCC represent a unique model for the study of interactions of the Shh pathway with other genes and pathways.
  • We constructed a tissue microarray (TMA) of 75 paired BCC and normal skin and analysed the expression of beta-catenin and RUNX3, nuclear effectors of the wingless-Int (Wnt) and bone morphogenetic protein/transforming growth factor-beta pathways, respectively.
  • In line with previous reports, we observed varying subcellular expression pattern of beta-catenin in BCC, with 31 cases (41%) showing nuclear accumulation.
  • In contrast, all the BCC cases tested by the TMA showed RUNX3 protein uniformly overexpressed in the nuclei of the cancer cells.
  • Our results indicate that although the deregulation of Wnt signalling could contribute to the pathogenesis of a subset of BCC, RUNX3 appears to be a universal downstream mediator of a constitutively active Shh pathway in BCC.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Core Binding Factor Alpha 3 Subunit / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Case-Control Studies. Cell Membrane / chemistry. Hedgehog Proteins / metabolism. Humans. Receptors, Cell Surface / metabolism. Signal Transduction. Skin / chemistry. Skin / cytology. Skin / pathology. Wnt Proteins / metabolism. beta Catenin / analysis. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767156.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / Wnt Proteins; 0 / beta Catenin; 0 / patched receptors
  •  go-up   go-down


95. Ishida M, Kushima R, Okabe H: Immunohistochemical demonstration of D2-40 in basal cell carcinomas of the skin. J Cutan Pathol; 2008 Oct;35(10):926-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical demonstration of D2-40 in basal cell carcinomas of the skin.
  • BACKGROUND: Recently, immunoreactivity to D2-40, a monoclonal antibody to lymphatic endothelium, was shown in a subgroup of epidermal basal cells and the majority of squamous cell carcinomas, but the immunoreactivity to this antibody has not been examined in basal cell carcinomas (BCCs) of the skin.
  • METHODS: Expression of D2-40 was analyzed together with that of cytokeratin (CK) 17, CK 19, CD34 and Ber-EP4 by immunohistochemical methods in 10 non-neoplastic skin tissue samples and 20 BCCs.
  • RESULTS: Immunoreactivity to D2-40 was shown in the basal cells at the outer root sheath (ORS) of hair follicles, similar to the CK 19 expression pattern.
  • D2-40 and CK 19 were focally expressed in 13/20 (65%) and 14/20 (70%) cases of BCCs, respectively, although the distributions of D2-40 and CK 19 immunoreactivity were not always identical.
  • However, BCC cells were constantly positive for CK 17 even tumor cells that were positive for D2-40 and/or CK 19.
  • Ber-EP4 was diffusely expressed in all BCCs, and CD34 was focally expressed in 2/20 cases.
  • CONCLUSION: Our results suggested that D2-40 immunoreactivity in BCCs showed differentiation toward the ORS of hair follicles.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / metabolism. Endothelium, Lymphatic / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537863.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / human epithelial antigen-125; 0 / monoclonal antibody D2-40
  •  go-up   go-down


96. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR).
  • : 1519 Background: Skin cancers are the most common malignancies in OTR.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • Capecitabine, an orally-administered prodrug of 5-FU, in combination with interferon was shown to be effective in the treatment of advanced SCC of the skin.
  • This study was to determine the efficacy of low-dose capecitabine in secondary prevention of the skin cancers in OTR.
  • METHODS: OTR who developed recurrent skin cancers, SCC, and/or basal cell carcinoma (BCC), were given low-dose capecitabine 1g/m2 divided in two daily doses, day 1-14 of 21-day treatment cycle.
  • Skin surveillances were performed by dermatologists every 1 to 3 months.
  • Cumulative incidence rates of SCC, BCC, and AK before and after treatment were scored and statistically compared for each patient with a non-parametric Wilcoxon signed-rank test.
  • Mean incidence rates of SCC, BCC, and AK before treatment were 0.45, 0.05, and 4.99 lesions per month, respectively.
  • Mean incidence rates of SCC, BCC, and AK after treatment were 0.22, 0.04, and 2.80 lesions per month, respectively.
  • The differences in incidence rates of SCC, BCC, and AK before and after treatment were 0.24, 0.02, and 2.08 lesions per month with p value of 0.048, 0.844, and 0.151, respectively.
  • Age and the number of transplants were not significantly related to the change in incidence rates for all skin lesion types.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Saetta AA, Stamatelli A, Karlou M, Michalopoulos NV, Patsouris E, Aroni K: Mutations of microsatellite instability target genes in sporadic basal cell carcinomas. Pathol Res Pract; 2007;203(12):849-55
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of microsatellite instability target genes in sporadic basal cell carcinomas.
  • The aim of our study was to investigate the prevalence of mutations in the above 4 MSI target genes in correlation with the MSI status of 75 basal cell carcinomas (BCCs), including aggressive-growth BCCs and cases with perineural invasion.
  • TGF-betaRII or hMSH3 frameshift mutations were identified in 5% of the BCCs, including two cases of aggressive-growth subtype, whereas there were no microsatellite alterations in the IGFIIR and hMSH6 genes.
  • Mutations at the mononucleotide repeats within the hMSH3 and TGF-betaRII genes occurred in certain BCCs, not always in association with MSI.
  • It seems likely that microsatellite alterations may be important in the development of individual cases of BCCs despite the low frequency of MSI in our cohort.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. DNA-Binding Proteins / metabolism. Frameshift Mutation. Microsatellite Instability. Protein-Serine-Threonine Kinases / genetics. Receptors, Transforming Growth Factor beta / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Humans. Male. Polymorphism, Single-Stranded Conformational

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950544.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MSH3 protein, human; 0 / Receptors, Transforming Growth Factor beta; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


98. Fang JY, Lee WR, Shen SC, Huang YL: Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas. J Dermatol Sci; 2006 May;42(2):101-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas.
  • METHOD: Liposomes containing egg phosphatidylcholine, cholesterol, or anionic surfactant in the presence of 15% ethanol were prepared.
  • The liposomes containing EGCG were injected into basal cell carcinomas (BCCs), melanomas, and colon tumors to examine the tumor uptake of the drug.
  • Liposomes were also incubated with a given number of BCC cells, and the cell viability was estimated.
  • RESULT: Almost no drug molecules were observed when free EGCG was administered to BCCs.
  • The liposomes without ethanol showed low or negligible enhancement on EGCG uptake in BCCs.
  • Liposomes protected EGCG from degradation, resulting in the induction of greater BCC death compared to that by free EGCG at lower concentrations.
  • CONCLUSION: These results suggest that the intratumor injection of liposomes containing EGCG with moderate modification is an effective approach for increasing EGCG deposition in BCCs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Catechin / administration & dosage. Catechin / analogs & derivatives. Drug Delivery Systems / methods. Liposomes / chemistry
  • [MeSH-minor] Animals. Cell Line, Tumor. Deoxycholic Acid / chemistry. Ethanol / pharmacology. Female. Humans. Melanoma / metabolism. Mice. Mice, Inbred BALB C. Tea

  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16423506.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 0 / Tea; 005990WHZZ / Deoxycholic Acid; 3K9958V90M / Ethanol; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  •  go-up   go-down


99. Griffiths RW, Suvarna SK, Stone J: Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg; 2005 Sep;58(6):795-805
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do basal cell carcinomas recur after complete conventional surgical excision?
  • For 1378 patients treated in the 11 years 1988-1998 by conventional excision of 1635 basal cell carcinomas, 1516 first index lesions were histologically completely excised.
  • All patients having more than one BCC excised were identified from the data base from 1988 to 2003 to give minimum 5 years follow for last treated primary lesions in 1998.
  • All incompletely excised lesions whether or not re-excised were excluded.
  • Two thirds of possible and probable recurrences occurred in the temple and forehead, although these sites represented only 22% of all lesions, which may rather suggest new lesions in an area of field change as opposed to residual disease.
  • These figures indicate there is a low order of probability for the incidence of recurrent basal cell carcinoma during minimum 5 years follow period after conventional surgical excision and conventional histological assessment of tumour resection margins.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2007;60(4):451-3 [17349608.001]
  • [CommentIn] J Plast Reconstr Aesthet Surg. 2006;59(11):1247 [17046636.001]
  • (PMID = 16086990.001).
  • [ISSN] 0007-1226
  • [Journal-full-title] British journal of plastic surgery
  • [ISO-abbreviation] Br J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Streeton CL, Gospodarevskaya E, Harris A: Treatment of basal cell carcinomas by general practitioners in Australia. Int J Dermatol; 2006 Apr;45(4):345-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of basal cell carcinomas by general practitioners in Australia.
  • BACKGROUND: Basal cell carcinomas (BCCs) are a relatively common form of skin damage in Australians, involving approximately 1 in 200 general practice encounters per year.
  • AIM: To determine current treatments and the associated healthcare resource costs of BCC therapy in Australia.
  • METHODS: A retrospective survey was undertaken relating to the treatment of patients presenting to their doctor with previously untreated BCCs.
  • Data were collected from a sample of general practitioners who were asked to randomly select two BCC patients from their medical records and complete a questionnaire.
  • RESULTS: One hundred and sixty-four patients were recruited into the study (59% male), who were treated for a total of 244 BCCs (average of 1.5 lesions per patient).
  • CONCLUSION: With a reported incidence in Australia of approximately 788 per 100,000 persons, BCCs are not inexpensive to treat for such a relatively common condition.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Physicians, Family. Practice Patterns, Physicians' / statistics & numerical data. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16650155.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  •  go-up   go-down






Advertisement